Pyruvate Dehydrogenase Deficiency

Mendelian MONDO:0019169 Pathograph 82 mitochondrial disease inborn error of metabolism

Pyruvate dehydrogenase deficiency is a genetically heterogeneous mitochondrial neurometabolic disorder caused by defects in structural subunits or regulatory enzymes of the pyruvate dehydrogenase complex. Reduced PDH complex activity blocks oxidative decarboxylation of pyruvate to acetyl-CoA, causing pyruvate and lactate accumulation, lactic acidosis, impaired TCA-cycle substrate supply, and neurological disease that ranges from fatal neonatal lactic acidosis to later-onset ataxia, dystonia, seizures, and developmental delay.

Ask OpenScientist

Ask a research question about Pyruvate Dehydrogenase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
13
Pathophys.
55
Phenotypes
82
Pathograph
7
Genes
4
Treatments
6
Subtypes
3
Trials
21
References
1
Deep Research
👪

Inheritance

2
X-linked dominant inheritance HP:0001423
PDHA1-related E1-alpha deficiency is X-linked dominant, with affected males often presenting severely and females affected variably by X-inactivation.
X-linked dominant inheritance
Show evidence (3 references)
ORPHA:765 SUPPORT Other
"X-linked dominant"
Orphanet records X-linked dominant inheritance for the PDH deficiency spectrum.
PMID:21908116 SUPPORT Human Clinical
"Genetic counseling is essential as PDHA1 deficiency (commonest defect) is X-linked although females can be affected due to unfavorable lyonization"
This review supports the X-linked PDHA1 inheritance pattern and explains why females can be affected.
PMID:38497591 SUPPORT Human Clinical
"Pyruvate dehydrogenase complex deficiency is in up to 90% caused by pathogenic variants in the X-linked PDHA1 gene."
This population-based PDHA1 carrier study supports PDHA1 as the dominant X-linked cause of PDH complex deficiency.
Autosomal recessive inheritance HP:0000007
Non-PDHA1 PDH complex structural-subunit, E3-binding-protein, and PDH phosphatase subtypes are inherited in autosomal recessive patterns.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:765 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for part of the PDH deficiency spectrum.
PMID:21908116 SUPPORT Human Clinical
"while PDHB and PDH phosphatase (PDP) deficiencies (much rarer defects) are of autosomal recessive inheritance."
This review identifies autosomal recessive inheritance for rarer non-PDHA1 subtypes.
◆

Subtypes

6
Pyruvate dehydrogenase E1-alpha deficiency MONDO:0010717
The most frequent PDH deficiency subtype, typically caused by PDHA1 variants and associated with X-linked inheritance, lactic acidosis, neurodevelopmental impairment, hypotonia, seizures, and movement disorders.
Show evidence (3 references)
ORPHA:79243 SUPPORT Other
"MONDO:0010717 | Exact"
Orphanet maps E1-alpha deficiency exactly to MONDO:0010717.
ORPHA:79243 SUPPORT Other
"PDHA1 | pyruvate dehydrogenase E1 subunit alpha 1 | hgnc:8806 | Disease-causing germline mutation(s) in"
Orphanet identifies PDHA1 as a disease-causing gene for this subtype.
ORPHA:79243 SUPPORT Other
"LONP1 | lon peptidase 1, mitochondrial | hgnc:9479 | Disease-causing germline mutation(s) in"
Orphanet also lists LONP1 as a disease-causing gene in the E1-alpha subtype record.
Pyruvate dehydrogenase E1-beta deficiency MONDO:0013580
A rare autosomal recessive PDH deficiency subtype caused by PDHB variants, classically associated with severe lactic acidosis, developmental delay, and hypotonia.
Show evidence (2 references)
ORPHA:255138 SUPPORT Other
"MONDO:0013580 | Exact"
Orphanet maps E1-beta deficiency exactly to MONDO:0013580.
ORPHA:255138 SUPPORT Other
"PDHB | pyruvate dehydrogenase E1 subunit beta | hgnc:8808 | Disease-causing germline mutation(s) in"
Orphanet identifies PDHB as the disease-causing gene for this subtype.
Pyruvate dehydrogenase E2 deficiency MONDO:0009502
A very rare PDH deficiency subtype caused by DLAT variants affecting the dihydrolipoamide S-acetyltransferase E2 component of the PDH complex.
Show evidence (2 references)
ORPHA:79244 SUPPORT Other
"MONDO:0009502 | Exact"
Orphanet maps E2 deficiency exactly to MONDO:0009502.
ORPHA:79244 SUPPORT Other
"DLAT | dihydrolipoamide S-acetyltransferase | hgnc:2896 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies DLAT loss-of-function variants as disease-causing for this subtype.
Pyruvate dehydrogenase E3 deficiency MONDO:0009529
DLD-related dihydrolipoamide dehydrogenase deficiency, which can present with PDH deficiency, branched-chain ketoacid dehydrogenase dysfunction, lactic acidosis, neurologic disease, and liver disease.
Show evidence (2 references)
ORPHA:2394 SUPPORT Other
"MONDO:0009529 | Exact"
Orphanet maps E3 deficiency exactly to MONDO:0009529.
ORPHA:2394 SUPPORT Other
"DLD | dihydrolipoamide dehydrogenase | hgnc:2898 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies DLD loss-of-function variants as disease-causing for this subtype.
Pyruvate dehydrogenase E3-binding protein deficiency MONDO:0009503
PDHX-related deficiency of the E3-binding protein/protein X component of the PDH complex, associated with variable lactic acidosis and neurologic dysfunction.
Show evidence (2 references)
ORPHA:255182 SUPPORT Other
"MONDO:0009503 | Exact"
Orphanet maps E3-binding protein deficiency exactly to MONDO:0009503.
ORPHA:255182 SUPPORT Other
"PDHX | pyruvate dehydrogenase complex component X | hgnc:21350 | Disease-causing germline mutation(s) in"
Orphanet identifies PDHX as the disease-causing gene for this subtype.
Pyruvate dehydrogenase phosphatase deficiency MONDO:0012120
PDP1-related deficiency of pyruvate dehydrogenase phosphatase, impairing dephosphorylation and activation of the PDH complex.
Show evidence (2 references)
ORPHA:79246 SUPPORT Other
"MONDO:0012120 | Exact"
Orphanet maps PDH phosphatase deficiency exactly to MONDO:0012120.
ORPHA:79246 SUPPORT Other
"PDP1 | pyruvate dehydrogenase phosphatase catalytic subunit 1 | hgnc:9279 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies PDP1 loss-of-function variants as disease-causing for this subtype.
⚙

Pathophysiology

13
PDH complex component or phosphatase deficiency
Pathogenic variants in PDH complex structural subunits or PDH phosphatase reduce PDH complex activity in the mitochondrial matrix. The canonical disease genes include PDHA1, PDHB, DLAT, DLD, PDHX, and PDP1.
PDHA1 link PDHB link DLAT link DLD link PDHX link PDP1 link
pyruvate dehydrogenase activity link ↓ DECREASED
mitochondrial matrix link
Downstream
Reduced pyruvate decarboxylation to acetyl-CoA
Decreased PDH complex activity Loss of PDH complex subunit or regulatory function is measured clinically as reduced PDH complex activity.
PDH complex enzyme activity The initiating molecular lesion lowers residual PDH complex enzyme activity.
DLAT-associated E2 neurodegenerative movement-retinal syndrome DLAT/E2 deficiency is a specific PDH complex subtype with retinal, neurodegenerative, movement, and basal-ganglia imaging findings.
DLD-associated E3 hepatic and branched-chain ketoacid dysfunction DLD/E3 deficiency is a specific PDH complex subtype that can include hepatic disease and branched-chain amino-acid abnormalities.
Abnormal facial shape Orphanet records craniofacial morphology as part of the PDH deficiency phenotype spectrum; the intermediate developmental mechanism is not resolved here.
Frontal bossing Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
High palate Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Trigonocephaly Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Narrow face Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Epicanthus Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Hypertelorism Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Long philtrum Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Wide nasal bridge Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Upslanted palpebral fissure Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
Pectus excavatum This skeletal phenotype is recorded in the PDH deficiency spectrum, but the intermediate morphogenetic mechanism is not specified.
Multiple lipomas This cutaneous phenotype is recorded in the PDH deficiency spectrum, but the intermediate mechanism is not specified.
Osteolytic defects of the middle phalanx of the 4th toe This skeletal phenotype is recorded in the PDH deficiency spectrum, but the intermediate mechanism is not specified.
Show evidence (2 references)
PMID:23622387 SUPPORT Human Clinical
"Pyruvate dehydrogenase has three main subunits, an additional E3-binding protein and two complex regulatory enzymes."
This review identifies the PDH complex subunit and regulatory architecture underlying the recognized deficiency subtypes.
PMID:23622387 SUPPORT Human Clinical
"Most frequent are deficiencies in PDH-E1α."
The review identifies E1-alpha deficiency as the most frequent subtype.
PDHA1 variant folding and assembly defects
Many PDHA1 E1-alpha pathogenic variants impair folding, E1 incorporation, or assembly of the PDH complex, lowering overall PDC activity.
PDHA1 link
pyruvate dehydrogenase activity link ↓ DECREASED
Downstream
Reduced pyruvate decarboxylation to acetyl-CoA
Show evidence (1 reference)
PMID:29445841 SUPPORT In Vitro
"Our studies suggest that pathogenic E1α variants may be associated with structural changes of PDC and impaired folding of E1α."
Yeast model and biochemical studies support variant-specific folding and assembly defects for PDHA1/E1-alpha.
LONP1 impaired phospho-E1-alpha proteolysis
Biallelic pathogenic LONP1 variants can impair mitochondrial LonP1 protease degradation of phosphorylated PDH E1-alpha. Accumulation of inhibitory phospho-E1-alpha reduces PDH activity and produces a PDH deficiency biochemical phenotype.
LONP1 link
mitochondrial phospho-E1-alpha proteolysis link ↓ DECREASED
mitochondrial matrix link
Downstream
Reduced pyruvate decarboxylation to acetyl-CoA Failed LonP1 degradation of phosphorylated E1-alpha increases the inhibitory phosphorylated E1-alpha pool, lowering PDH activity and pyruvate oxidation.
Decreased PDH complex activity Patient fibroblasts with biallelic LONP1 variants showed reduced PDH activity through inhibitory E1-alpha phosphorylation.
Show evidence (2 references)
PMID:30304514 SUPPORT In Vitro
"We demonstrated that in the siblings' fibroblasts, PDH dysfunction was caused by increased levels of the phosphorylated E1α subunit of PDH, which inhibits enzyme activity."
Patient-derived fibroblast experiments connect LONP1 variant cells to inhibitory phospho-E1-alpha accumulation and PDH dysfunction.
PMID:30304514 SUPPORT In Vitro
"Furthermore, in vitro studies demonstrated that purified LonP1-P761L failed to degrade phosphorylated E1α, in contrast to wild-type LonP1."
Biochemical evidence supports the specific loss of LonP1-mediated phospho-E1-alpha proteolysis.
Thiamine-responsive PDHA1 residual activity
Selected PDHA1 variants can retain thiamine-responsive residual activity, producing milder movement-disorder presentations that may improve with high-dose thiamine rather than representing broad responsiveness of all PDH complex subtypes.
PDHA1 link
pyruvate dehydrogenase activity link ↓ DECREASED
Downstream
Reduced pyruvate decarboxylation to acetyl-CoA
Show evidence (2 references)
PMID:26008863 SUPPORT Human Clinical
"PDH deficiency caused by a Leu216Ser mutation in PDHA1."
This case identifies a PDHA1 variant in a thiamine-responsive PDH deficiency presentation.
PMID:26008863 SUPPORT Human Clinical
"Dystonia completely remitted after high doses of thiamine, remaining free of symptoms after 3 years of follow up."
The same case supports thiamine responsiveness in a selected PDHA1 presentation.
Reduced pyruvate decarboxylation to acetyl-CoA
PDH complex deficiency blocks oxidative decarboxylation of pyruvate to acetyl-CoA, weakening the link between glycolysis and the TCA cycle.
pyruvate decarboxylation to acetyl-CoA link ↓ DECREASED tricarboxylic acid cycle link ↓ DECREASED
mitochondrial matrix link
Downstream
Lactate and pyruvate accumulation
Cerebral energy failure and neurodevelopmental injury
Show evidence (2 references)
PMID:21908116 SUPPORT Human Clinical
"The pyruvate dehydrogenase complex (PDHc) is a mitochondrial matrix multienzyme complex that provides the link between glycolysis and the tricarboxylic acid (TCA) cycle by catalyzing the conversion of pyruvate into acetyl-CoA."
This directly supports the PDH complex step that is deficient in the disorder.
PMID:23467562 SUPPORT Other
"Pyruvate dehydrogenase complex (PDHC), an enzyme complex that catalyzes the irreversible conversion of pyruvate into acetyl-CoA (coenzyme A), plays a central role in linking glycolysis to the tricarboxylic acid (TCA) cycle and lipogenic pathways"
This mechanistic review establishes PDHC as the pyruvate-to-acetyl-CoA link whose activity is deficient.
PDK-regulated residual PDH activity
Residual PDH complex activity is modulated by phosphorylation of E1-alpha by pyruvate dehydrogenase kinases and dephosphorylation by PDH phosphatases, making kinase inhibition a plausible treatment target in selected variants.
PDHA1 link
pyruvate decarboxylation to acetyl-CoA link ↕ DYSREGULATED
Downstream
Reduced pyruvate decarboxylation to acetyl-CoA
Show evidence (1 reference)
PMID:23467562 SUPPORT In Vitro
"Phosphorylation of specific serine residues of the E1α subunit of PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC activity."
This supports phosphorylation state as a regulator of residual PDH complex activity.
Lactate and pyruvate accumulation
When pyruvate cannot efficiently enter the PDH complex reaction, pyruvate and lactate accumulate in blood, CSF, and tissues, producing the classic biochemical pattern of lactic acidosis with a lactate:pyruvate ratio often not exceeding 20.
pyruvate metabolic process link ↕ DYSREGULATED
Downstream
Congenital lactic acidosis
Lactate Impaired pyruvate oxidation increases lactate in blood and CSF.
Pyruvate Blocked PDH flux leaves pyruvate insufficiently cleared.
Increased circulating lactate Lactate accumulation appears clinically as increased circulating lactate concentration.
Increased serum pyruvate Pyruvate accumulation appears clinically as increased circulating pyruvate concentration.
Show evidence (2 references)
PMID:22896851 SUPPORT Human Clinical
"Although the clinical spectrum of PDC deficiency is broad, the dominant clinical phenotype includes presentation during the first year of life; neurological and neuromuscular degeneration; structural lesions revealed by neuroimaging; lactic acidosis and a blood lactate:pyruvate ratio ≤ 20."
The cohort review directly supports lactic acidosis and the characteristic lactate:pyruvate ratio pattern.
PMID:23467562 SUPPORT Other
"A deficiency of any enzyme in these pathways results in inadequate removal of pyruvate and lactate from blood and tissues and causes lactic acidosis."
The mechanistic review explains pyruvate and lactate accumulation downstream of impaired pyruvate oxidation.
Cerebral energy failure and neurodevelopmental injury
Reduced acetyl-CoA delivery to the TCA cycle and mitochondrial energy production injures the developing brain, contributing to structural brain anomalies, seizures, hypotonia, ataxia, and developmental delay.
neuron link
oxidative phosphorylation link ↓ DECREASED
brain link
Downstream
Neurodevelopmental delay and hypotonia
Seizures and movement disorders
Aplasia/Hypoplasia of the corpus callosum Energy failure in brain development is associated with structural brain malformations, including corpus-callosum dysgenesis.
Ventriculomegaly Structural brain abnormalities in PDH complex deficiency include ventriculomegaly.
Neurodegeneration Chronic cerebral energy failure contributes to progressive neurological degeneration.
Microcephaly Microcephaly is linked to the neurodevelopmental injury spectrum, with intermediate growth mechanisms not resolved here.
Show evidence (2 references)
PMID:21908116 SUPPORT Human Clinical
"In severe deficiency states the resulting energy deficit impacts on brain development in utero resulting in structural brain anomalies and epilepsy."
This review links PDH-deficiency energy failure to brain maldevelopment and epilepsy.
PMID:21908116 SUPPORT Human Clinical
"Epileptogenesis in PDHc deficiency is linked to energy failure, development of structural brain anomalies and abnormal neurotransmitter metabolism."
This supports seizures as a downstream consequence of cerebral energy failure and abnormal neurotransmitter metabolism.
Congenital lactic acidosis
Lactate accumulation causes congenital or early-onset lactic acidosis, often severe in neonatal presentations and associated with respiratory compensation such as tachypnea.
Downstream
Lactic acidosis Congenital lactic acidosis is the clinical manifestation of lactate accumulation.
Tachypnea Tachypnea can reflect respiratory compensation during metabolic acidosis.
Dyspnea Dyspnea is recorded in the PDH deficiency phenotype spectrum and can accompany severe metabolic decompensation.
Lethargy Metabolic decompensation from lactic acidosis contributes to lethargy.
Feeding difficulties in infancy Feeding difficulty is part of the early severe presentation; the immediate intermediate is not resolved in this graph.
Vomiting Vomiting is recorded in the E3 deficiency metabolic-decompensation phenotype spectrum.
Hypoglycemia Hypoglycemia is recorded in E3 deficiency and grouped here with metabolic decompensation features.
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"Manifestations range from often fatal, severe, neonatal lactic acidosis to later-onset neurological disorders."
Orphanet identifies severe neonatal lactic acidosis as a key manifestation.
Neurodevelopmental delay and hypotonia
Neurodevelopmental delay and hypotonia are among the most common clinical signs in the 371-patient PDC deficiency spectrum.
Downstream
Hypotonia Hypotonia is one of the commonest signs in the PDC deficiency spectrum.
Global developmental delay Global developmental delay is the clinical phenotype captured by this neurodevelopmental injury node.
Cerebral palsy PDH deficiency can resemble nonprogressive cerebral palsy, especially in female PDHA1 deficiency.
Growth delay Growth delay is part of the broader developmental phenotype spectrum.
Intrauterine growth retardation Intrauterine growth restriction is part of the broader developmental phenotype spectrum.
Show evidence (1 reference)
PMID:22896851 SUPPORT Human Clinical
"Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency."
The large review directly identifies neurodevelopmental delay and hypotonia as the commonest signs.
Seizures and movement disorders
Severe and milder PDH deficiency states can produce seizures, ataxia, dystonia, and other movement disorders through energy failure, structural brain anomalies, and neurotransmitter disturbance.
Downstream
Seizure Seizures are a core manifestation of PDH-related cerebral energy failure.
Ataxia Milder PDH deficiency states can include ataxia.
Spasticity Spasticity is a pyramidal motor manifestation within the PDH neurologic phenotype spectrum.
Dysarthria Dysarthria is grouped with PDH-related movement and motor-control dysfunction.
Choreoathetosis Choreoathetosis is grouped with PDH-related movement disorder manifestations.
Gait disturbance Gait disturbance follows from ataxic, dystonic, or pyramidal motor involvement.
Dystonia Dystonia is directly supported as a PDH deficiency manifestation.
Tremor Tremor is grouped with the movement-disorder manifestations of PDH deficiency.
Abnormal pyramidal sign Pyramidal signs reflect motor pathway involvement in the PDH neurologic phenotype.
Abnormality of eye movement Abnormal eye movements are grouped with the neurologic movement-control phenotype.
Paroxysmal dystonia Paroxysmal dystonia is a subtype-specific dystonic manifestation.
Broad-based gait Broad-based gait is a subtype-specific gait manifestation linked to movement-system involvement.
Lower limb hyperreflexia Lower-limb hyperreflexia is grouped with pyramidal motor involvement.
Atypical behavior Atypical behavior is grouped with neurologic involvement, with intermediate neurobehavioral mechanisms not resolved here.
Show evidence (2 references)
PMID:21908116 SUPPORT Human Clinical
"Milder deficiency states present with variable manifestations that include cognitive delay, ataxia, and seizures."
This supports ataxia and seizures in milder PDH deficiency.
PMID:26008863 SUPPORT Human Clinical
"Dystonia precipitated by exercise may be the only symptom of a PDH deficiency"
This case report and mini-review support dystonia as part of the PDH deficiency spectrum.
DLAT-associated E2 neurodegenerative movement-retinal syndrome
The DLAT/E2 subtype is characterized by childhood lactic acidosis and neurological dysfunction, with Orphanet phenotype rows documenting retinal degeneration, neurodegeneration, paroxysmal dystonia, broad-based gait, lower-limb hyperreflexia, globus-pallidus imaging abnormalities, atypical behavior, and low circulating vitamin B1.
DLAT link
Downstream
Retinal degeneration Retinal degeneration is an E2-deficiency neurologic sensory phenotype.
Neurodegeneration Neurodegeneration is recorded as a frequent E2-deficiency manifestation.
Paroxysmal dystonia Paroxysmal dystonia is recorded as a frequent E2-deficiency movement phenotype.
Broad-based gait Broad-based gait is recorded as a frequent E2-deficiency gait phenotype.
Lower limb hyperreflexia Lower-limb hyperreflexia is recorded as a frequent E2-deficiency pyramidal sign.
Eye of the tiger anomaly of globus pallidus This globus-pallidus imaging sign is recorded in E2 deficiency.
Atypical behavior Atypical behavior is recorded in E2 deficiency, with intermediate neurobehavioral mechanisms not resolved here.
Low levels of vitamin B1 Low vitamin B1 is recorded in the E2 deficiency phenotype table; its mechanistic role is not resolved here.
Show evidence (2 references)
ORPHA:79244 SUPPORT Other
"A very rare form of pyruvate dehydrogenase deficiency (PDHD) characterized by variable lactic acidosis and neurological dysfunction, mainly appearing during childhood."
Orphanet defines E2 deficiency as a childhood PDH deficiency subtype with lactic acidosis and neurologic dysfunction.
ORPHA:79244 SUPPORT Other
"DLAT | dihydrolipoamide S-acetyltransferase | hgnc:2896 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies DLAT loss-of-function variants as causal for the E2 subtype.
DLD-associated E3 hepatic and branched-chain ketoacid dysfunction
The DLD/E3 subtype can present with early lactic acidosis, delayed development, later neurologic dysfunction, or liver disease, and Orphanet synonymizes it with E3-deficient maple syrup urine disease. This captures the E3-subtype hepatic and branched-chain amino-acid phenotype branch.
DLD link
Downstream
Hepatic failure Hepatic failure is an E3-deficiency systemic manifestation of DLD-related disease.
Hypoglycemia Hypoglycemia is recorded in E3 deficiency and grouped with metabolic decompensation features.
Vomiting Vomiting is recorded in the E3 deficiency metabolic-decompensation phenotype spectrum.
Hepatomegaly Hepatomegaly is an E3-deficiency systemic manifestation of DLD-related disease.
Hepatic encephalopathy Hepatic encephalopathy is an E3-deficiency systemic manifestation of DLD-related disease.
Elevated circulating hepatic transaminase concentration Elevated transaminases are an E3-deficiency hepatic biochemical manifestation.
Elevated plasma branched chain amino acids DLD/E3 deficiency overlaps with E3-deficient maple syrup urine disease, producing branched-chain amino acid abnormalities.
Hypercoagulability Hypercoagulability is recorded in E3 deficiency, with intermediate mechanisms not resolved here.
Show evidence (2 references)
ORPHA:2394 SUPPORT Other
"Pyruvate dehydrogenase E3 deficiency is a very rare subtype of pyruvate dehydrogenase deficiency (PDHD) characterized by either early-onset lactic acidosis and delayed development, later-onset neurological dysfunction or liver disease."
Orphanet defines E3 deficiency as a PDH deficiency subtype with lactic acidosis, developmental delay, neurologic dysfunction, or liver disease.
ORPHA:2394 SUPPORT Other
"E3-deficient maple syrup urine disease"
The synonym supports the E3 subtype's overlap with branched-chain ketoacid dehydrogenase dysfunction.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pyruvate Dehydrogenase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

55
Digestive 4
Feeding difficulties in infancy VERY_FREQUENT Feeding difficulties in infancy (HP:0008872)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0008872 | Feeding difficulties in infancy | Very frequent (99-80%)"
Orphanet provides structured frequency support for infant feeding difficulties.
Hepatic failure OCCASIONAL Hepatic failure (HP:0001399)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0001399 | Hepatic failure | Occasional (29-5%)"
Orphanet provides subtype-specific support for hepatic failure in E3 deficiency.
Vomiting VERY_FREQUENT Vomiting (HP:0002013)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0002013 | Vomiting | Very frequent (99-80%)"
Orphanet provides subtype-specific frequency support for vomiting in E3 deficiency.
Hepatomegaly FREQUENT Hepatomegaly (HP:0002240)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0002240 | Hepatomegaly | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for hepatomegaly in E3 deficiency.
Eye 2
Hypertelorism OCCASIONAL Hypertelorism (HP:0000316)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000316 | Hypertelorism | Occasional (29-5%)"
Orphanet provides structured support for hypertelorism.
Abnormality of eye movement FREQUENT Abnormality of eye movement (HP:0000496)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000496 | Abnormality of eye movement | Frequent (79-30%)"
Orphanet provides structured frequency support for abnormal eye movements.
Head and Neck 7
Abnormal facial shape VERY_FREQUENT Abnormal facial shape (HP:0001999)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001999 | Abnormal facial shape | Very frequent (99-80%)"
Orphanet provides structured frequency support for abnormal facial shape.
Microcephaly FREQUENT Microcephaly (HP:0000252)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000252 | Microcephaly | Frequent (79-30%)"
Orphanet provides structured frequency support for microcephaly.
Frontal bossing OCCASIONAL Frontal bossing (HP:0002007)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0002007 | Frontal bossing | Occasional (29-5%)"
Orphanet provides structured support for frontal bossing.
High palate OCCASIONAL High palate (HP:0000218)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000218 | High palate | Occasional (29-5%)"
Orphanet provides structured support for high palate.
Epicanthus OCCASIONAL Epicanthus (HP:0000286)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000286 | Epicanthus | Occasional (29-5%)"
Orphanet provides structured support for epicanthus.
Long philtrum OCCASIONAL Long philtrum (HP:0000343)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000343 | Long philtrum | Occasional (29-5%)"
Orphanet provides structured support for long philtrum.
Upslanted palpebral fissure OCCASIONAL Upslanted palpebral fissure (HP:0000582)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000582 | Upslanted palpebral fissure | Occasional (29-5%)"
Orphanet provides structured support for upslanted palpebral fissures.
Metabolism 4
Lactic acidosis FREQUENT Lactic acidosis (HP:0003128)
Show evidence (2 references)
PMID:22896851 SUPPORT Human Clinical
"lactic acidosis and a blood lactate:pyruvate ratio ≤ 20"
The cohort review supports lactic acidosis as part of the dominant PDH deficiency phenotype.
ORPHA:79243 SUPPORT Other
"HP:0003128 | Lactic acidosis | Frequent (79-30%)"
Orphanet provides frequency support for lactic acidosis in the E1-alpha subtype.
Hypoglycemia FREQUENT Hypoglycemia (HP:0001943)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0001943 | Hypoglycemia | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for hypoglycemia in E3 deficiency.
Elevated circulating hepatic transaminase concentration FREQUENT Elevated circulating hepatic transaminase concentration (HP:0002910)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0002910 | Elevated circulating hepatic transaminase concentration | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for transaminase elevation in E3 deficiency.
Elevated plasma branched chain amino acids FREQUENT Elevated circulating branched chain amino acid concentration (HP:0008344)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0008344 | Elevated plasma branched chain amino acids | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for elevated branched-chain amino acids in E3 deficiency.
Musculoskeletal 4
Hypotonia VERY_FREQUENT Hypotonia (HP:0001252)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001252 | Hypotonia | Very frequent (99-80%)"
Orphanet provides structured frequency support for hypotonia.
Spasticity FREQUENT Spasticity (HP:0001257)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001257 | Spasticity | Frequent (79-30%)"
Orphanet provides structured frequency support for spasticity.
Pectus excavatum OCCASIONAL Pectus excavatum (HP:0000767)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000767 | Pectus excavatum | Occasional (29-5%)"
Orphanet provides structured support for pectus excavatum.
Multiple lipomas OCCASIONAL Multiple lipomas (HP:0001012)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001012 | Multiple lipomas | Occasional (29-5%)"
Orphanet provides structured support for multiple lipomas.
Nervous System 12
Seizure FREQUENT Seizure (HP:0001250)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001250 | Seizure | Frequent (79-30%)"
Orphanet provides structured frequency support for seizures.
Global developmental delay FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001263 | Global developmental delay | Frequent (79-30%)"
Orphanet provides structured frequency support for global developmental delay.
Ataxia FREQUENT Ataxia (HP:0001251)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001251 | Ataxia | Frequent (79-30%)"
Orphanet provides structured frequency support for ataxia.
Dysarthria FREQUENT Dysarthria (HP:0001260)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001260 | Dysarthria | Frequent (79-30%)"
Orphanet provides structured frequency support for dysarthria.
Choreoathetosis FREQUENT Choreoathetosis (HP:0001266)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001266 | Choreoathetosis | Frequent (79-30%)"
Orphanet provides structured frequency support for choreoathetosis.
Gait disturbance FREQUENT Gait disturbance (HP:0001288)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001288 | Gait disturbance | Frequent (79-30%)"
Orphanet provides structured frequency support for gait disturbance.
Dystonia OCCASIONAL Dystonia (HP:0001332)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001332 | Dystonia | Occasional (29-5%)"
Orphanet provides structured frequency support for dystonia.
Tremor FREQUENT Tremor (HP:0001337)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001337 | Tremor | Frequent (79-30%)"
Orphanet provides structured frequency support for tremor.
Lethargy VERY_FREQUENT Lethargy (HP:0001254)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001254 | Lethargy | Very frequent (99-80%)"
Orphanet provides structured frequency support for lethargy.
Ventriculomegaly OCCASIONAL Ventriculomegaly (HP:0002119)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0002119 | Ventriculomegaly | Occasional (29-5%)"
Orphanet provides structured support for ventriculomegaly.
Atypical behavior FREQUENT Atypical behavior (HP:0000708)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0000708 | Atypical behavior | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for atypical behavior in E2 deficiency.
Hepatic encephalopathy FREQUENT Hepatic encephalopathy (HP:0002480)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0002480 | Hepatic encephalopathy | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for hepatic encephalopathy in E3 deficiency.
Respiratory 2
Tachypnea FREQUENT Tachypnea (HP:0002789)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0002789 | Tachypnea | Frequent (79-30%)"
Orphanet provides structured frequency support for tachypnea.
Dyspnea OCCASIONAL Dyspnea (HP:0002094)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0002094 | Dyspnea | Occasional (29-5%)"
Orphanet provides structured frequency support for dyspnea.
Growth 2
Growth delay VERY_FREQUENT Growth delay (HP:0001510)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001510 | Growth delay | Very frequent (99-80%)"
Orphanet provides structured frequency support for growth delay.
Intrauterine growth retardation FREQUENT Intrauterine growth retardation (HP:0001511)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0001511 | Intrauterine growth retardation | Frequent (79-30%)"
Orphanet provides structured frequency support for intrauterine growth restriction.
Other 18
Increased circulating lactate VERY_FREQUENT Increased circulating lactate concentration (HP:0002151)
Show evidence (1 reference)
ORPHA:79243 SUPPORT Other
"HP:0002151 | Increased circulating lactate concentration | Very frequent (99-80%)"
Orphanet provides structured frequency support for increased circulating lactate in E1-alpha deficiency.
Increased serum pyruvate FREQUENT Increased circulating pyruvate concentration (HP:0003542)
Show evidence (1 reference)
ORPHA:79243 SUPPORT Other
"HP:0003542 | Increased serum pyruvate | Frequent (79-30%)"
Orphanet provides structured frequency support for increased serum pyruvate in E1-alpha deficiency.
Decreased PDH complex activity FREQUENT Decreased activity of the pyruvate dehydrogenase complex (HP:0002928)
Show evidence (1 reference)
ORPHA:255138 SUPPORT Other
"HP:0002928 | Decreased activity of the pyruvate dehydrogenase complex | Frequent (79-30%)"
Orphanet provides structured support for decreased PDH complex activity.
Abnormal pyramidal sign FREQUENT Abnormal pyramidal sign (HP:0007256)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0007256 | Abnormal pyramidal sign | Frequent (79-30%)"
Orphanet provides structured frequency support for pyramidal signs.
Cerebral palsy OCCASIONAL Cerebral palsy (HP:0100021)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0100021 | Cerebral palsy | Occasional (29-5%)"
Orphanet provides structured frequency support for cerebral-palsy-like presentation.
Aplasia/Hypoplasia of the corpus callosum FREQUENT Aplasia/Hypoplasia of the corpus callosum (HP:0007370)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0007370 | Aplasia/Hypoplasia of the corpus callosum | Frequent (79-30%)"
Orphanet provides structured frequency support for corpus-callosum aplasia/hypoplasia.
Trigonocephaly OCCASIONAL Trigonocephaly (HP:0000243)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000243 | Trigonocephaly | Occasional (29-5%)"
Orphanet provides structured support for trigonocephaly.
Narrow face OCCASIONAL Narrow face (HP:0000275)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000275 | Narrow face | Occasional (29-5%)"
Orphanet provides structured support for narrow face.
Wide nasal bridge OCCASIONAL Wide nasal bridge (HP:0000431)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0000431 | Wide nasal bridge | Occasional (29-5%)"
Orphanet provides structured support for wide nasal bridge.
Osteolytic defects of the middle phalanx of the 4th toe FREQUENT Osteolytic defects of the middle phalanx of the 4th toe (HP:0100453)
Show evidence (1 reference)
ORPHA:765 SUPPORT Other
"HP:0100453 | Osteolytic defects of the middle phalanx of the 4th toe | Frequent (79-30%)"
Orphanet provides structured frequency support for this skeletal finding.
Retinal degeneration FREQUENT Retinal degeneration (HP:0000546)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0000546 | Retinal degeneration | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for retinal degeneration in E2 deficiency.
Neurodegeneration FREQUENT Neurodegeneration (HP:0002180)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0002180 | Neurodegeneration | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for neurodegeneration in E2 deficiency.
Paroxysmal dystonia FREQUENT Paroxysmal dystonia (HP:0002268)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0002268 | Paroxysmal dystonia | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for paroxysmal dystonia in E2 deficiency.
Broad-based gait FREQUENT Broad-based gait (HP:0002136)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0002136 | Broad-based gait | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for broad-based gait in E2 deficiency.
Lower limb hyperreflexia FREQUENT Lower limb hyperreflexia (HP:0002395)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0002395 | Lower limb hyperreflexia | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for lower limb hyperreflexia in E2 deficiency.
Eye of the tiger anomaly of globus pallidus FREQUENT Eye of the tiger anomaly of globus pallidus (HP:0002454)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0002454 | Eye of the tiger anomaly of globus pallidus | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for this E2-deficiency neuroimaging feature.
Low levels of vitamin B1 VERY_FREQUENT Decreased circulating vitamin B1 concentration (HP:0100503)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"HP:0100503 | Low levels of vitamin B1 | Very frequent (99-80%)"
Orphanet provides subtype-specific frequency support for low vitamin B1 levels in E2 deficiency.
Hypercoagulability FREQUENT Hypercoagulability (HP:0100724)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"HP:0100724 | Hypercoagulability | Frequent (79-30%)"
Orphanet provides subtype-specific frequency support for hypercoagulability in E3 deficiency.
🧬

Genetic Associations

7
PDHA1 (Causal X-linked pathogenic variant)
Show evidence (2 references)
ORPHA:79243 SUPPORT Other
"PDHA1 | pyruvate dehydrogenase E1 subunit alpha 1 | hgnc:8806 | Disease-causing germline mutation(s) in"
Orphanet identifies PDHA1 as disease-causing for E1-alpha deficiency.
PMID:38497591 SUPPORT Human Clinical
"Pyruvate dehydrogenase complex deficiency is in up to 90% caused by pathogenic variants in the X-linked PDHA1 gene."
This supports PDHA1 as the predominant causal gene in PDH complex deficiency.
LONP1 (Causal germline pathogenic variant in the E1-alpha subtype record)
Show evidence (2 references)
ORPHA:79243 SUPPORT Other
"LONP1 | lon peptidase 1, mitochondrial | hgnc:9479 | Disease-causing germline mutation(s) in"
Orphanet identifies LONP1 as disease-causing in the E1-alpha deficiency subtype record.
PMID:30304514 SUPPORT Human Clinical
"We identified a novel homozygous missense LONP1 variant, c.2282 C > T, (p.Pro761Leu), by whole-exome and Sanger sequencing in two siblings born to healthy consanguineous parents."
Human sibling sequencing evidence supports LONP1 as a causal germline gene for this PDH deficiency presentation.
PDHB (Causal biallelic pathogenic variant)
Show evidence (1 reference)
ORPHA:255138 SUPPORT Other
"PDHB | pyruvate dehydrogenase E1 subunit beta | hgnc:8808 | Disease-causing germline mutation(s) in"
Orphanet identifies PDHB as disease-causing for E1-beta deficiency.
DLAT (Causal biallelic loss-of-function variant)
Show evidence (1 reference)
ORPHA:79244 SUPPORT Other
"DLAT | dihydrolipoamide S-acetyltransferase | hgnc:2896 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies DLAT loss-of-function variants as disease-causing for E2 deficiency.
DLD (Causal biallelic loss-of-function variant)
Show evidence (1 reference)
ORPHA:2394 SUPPORT Other
"DLD | dihydrolipoamide dehydrogenase | hgnc:2898 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies DLD loss-of-function variants as disease-causing for E3 deficiency.
PDHX (Causal biallelic pathogenic variant)
Show evidence (1 reference)
ORPHA:255182 SUPPORT Other
"PDHX | pyruvate dehydrogenase complex component X | hgnc:21350 | Disease-causing germline mutation(s) in"
Orphanet identifies PDHX as disease-causing for E3-binding protein deficiency.
PDP1 (Causal biallelic loss-of-function variant)
Show evidence (1 reference)
ORPHA:79246 SUPPORT Other
"PDP1 | pyruvate dehydrogenase phosphatase catalytic subunit 1 | hgnc:9279 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies PDP1 loss-of-function variants as disease-causing for PDH phosphatase deficiency.
💊

Treatments

4
Ketogenic diet
Action: dietary intervention MAXO:0000088
Ketogenic diet is the best-supported disease-directed management strategy, bypassing the PDH block by providing ketone-derived acetyl-CoA and improving epilepsy, ataxia, sleep, language, social function, and hospitalization frequency in many patients.
Mechanism Target:
BYPASSES Reduced pyruvate decarboxylation to acetyl-CoA — Ketogenic diet provides an alternative acetyl-CoA source downstream of the PDH block.
Show evidence (2 references)
PMID:28101805 SUPPORT Human Clinical
"The treatment had a positive effect mainly in the areas of epilepsy, ataxia, sleep disturbance, speech/language development, social functioning, and frequency of hospitalizations."
The Swedish cohort supports clinical benefit from ketogenic diet across several PDH deficiency outcomes.
PMID:21908116 SUPPORT Human Clinical
"The use of the ketogenic diet bypasses the metabolic block, by providing a direct source of acetyl-CoA, leading to amelioration of some symptoms."
This review directly supports the bypass mechanism for ketogenic diet in PDH deficiency.
Thiamine supplementation
Action: nutritional supplementation MAXO:0000106
Agent: thiamine ↗
High-dose thiamine may benefit selected thiamine-responsive PDHA1 variants, particularly milder movement-disorder presentations.
Mechanism Target:
MODULATES Thiamine-responsive PDHA1 residual activity — Thiamine targets selected PDHA1/E1-alpha presentations with residual thiamine-responsive activity.
Show evidence (1 reference)
PMID:26008863 SUPPORT Human Clinical
"Dystonia completely remitted after high doses of thiamine, remaining free of symptoms after 3 years of follow up."
A PDHA1 case report supports high-dose thiamine responsiveness in a selected presentation.
Dichloroacetate
Action: Pharmacotherapy NCIT:C15986
Agent: dichloroacetate ↗
Dichloroacetate is a targeted pharmacologic approach intended to increase PDH complex catalytic activity and stability. Human trial evidence supports lactate lowering but not broad neurologic or clinical outcome improvement.
Mechanism Target:
MODULATES PDK-regulated residual PDH activity — Dichloroacetate inhibits PDK-mediated PDH inactivation and can reduce lactate.
MODULATES Lactate and pyruvate accumulation — DCA can blunt lactate increases in congenital lactic acidosis.
Show evidence (4 references)
PMID:16651305 PARTIAL Human Clinical
"DCA significantly decreased the rise in blood lactate caused by carbohydrate feeding."
A randomized trial supports lactate reduction but not global clinical benefit.
PMID:16651305 PARTIAL Human Clinical
"However, it did not improve neurologic or other measures of clinical outcome."
The same trial limits the claim to biochemical effect rather than proven clinical improvement.
PMID:18411236 PARTIAL Human Clinical
"Although continued dichloroacetate exposure is associated with evidence of peripheral neuropathy, it cannot be determined whether this is attributable mainly to the drug or to progression of underlying disease."
Long-term follow-up supports a safety concern and reinforces that DCA is not an uncomplicated disease-modifying therapy.
+ 1 more reference
Sodium phenylbutyrate
Action: Pharmacotherapy NCIT:C15986
Agent: sodium phenylbutyrate ↗
Sodium phenylbutyrate is an investigational pharmacologic approach that can inhibit PDK-mediated E1-alpha phosphorylation, increase PDH complex activity in responsive cells and models, and is under clinical study for PDH complex deficiency.
Mechanism Target:
MODULATES PDK-regulated residual PDH activity — Phenylbutyrate can inhibit PDK-mediated phosphorylation and increase active PDH complex in selected models.
Show evidence (3 references)
PMID:23467562 PARTIAL In Vitro
"Phenylbutyrate increases PDHC activity in fibroblasts from PDHC-deficient patients harboring various molecular defects"
Patient fibroblast evidence supports increased PDH activity, but this is not a completed clinical efficacy trial.
PMID:35996497 PARTIAL Other
"Phenylbutyrate can only be used on patients with certain pathogenic variants (p.P221L, p.R234G, p.G249R, p.R349C, p.R349H) on the PDH protein."
This review supports variant-specific, investigational use rather than universal treatment.
clinicaltrials:NCT03734263 SUPPORT Human Clinical
"In this study phenylbutyrate is used for patients with pyruvate dehydrogenase complex deficiency."
The completed Phase 2 trial record supports disease-specific clinical investigation of phenylbutyrate.
🔬

Biochemical Markers

3
Lactate (INCREASED)
Context: Blood and CSF lactate are often elevated in PDH deficiency.
Pathograph Readouts
Readout Of Lactate and pyruvate accumulation Positive Diagnostic
Elevated blood or CSF lactate reports the lactate arm of pyruvate-to-lactate accumulation downstream of impaired PDH flux.
Show evidence (1 reference)
PMID:22896851 SUPPORT Human Clinical
"Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting."
The cohort review supports blood lactate as a measurable biochemical abnormality associated with PDH deficiency severity.
Show evidence (1 reference)
PMID:22896851 SUPPORT Human Clinical
"Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting."
The clinical review supports elevated lactate as a disease-severity and mortality-associated biochemical abnormality.
Pyruvate (INCREASED)
Context: Pyruvate accumulates when oxidative decarboxylation by the PDH complex is deficient.
Pathograph Readouts
Readout Of Lactate and pyruvate accumulation Positive Diagnostic
Elevated pyruvate reports impaired clearance of the glycolytic end product when oxidative decarboxylation by PDH is blocked.
Show evidence (1 reference)
PMID:23467562 SUPPORT Other
"A deficiency of any enzyme in these pathways results in inadequate removal of pyruvate and lactate from blood and tissues and causes lactic acidosis."
This mechanistic review supports pyruvate accumulation as a biochemical readout of impaired pyruvate oxidation.
Show evidence (1 reference)
PMID:23467562 SUPPORT Other
"A deficiency of any enzyme in these pathways results in inadequate removal of pyruvate and lactate from blood and tissues and causes lactic acidosis."
This supports pyruvate accumulation downstream of impaired pyruvate oxidation.
PDH complex enzyme activity (DECREASED)
Context: Residual enzyme activity is reduced and correlates with severity in severe presentations.
Pathograph Readouts
Readout Of Reduced pyruvate decarboxylation to acetyl-CoA Negative Diagnostic
Lower residual PDH complex activity directly reports the impaired pyruvate-to-acetyl-CoA catalytic step.
Show evidence (1 reference)
PMID:22896851 SUPPORT Human Clinical
"lower residual enzyme activities than subjects who were still alive at the time of reporting."
The clinical review supports reduced residual enzyme activity as a measurable biochemical readout of the PDH catalytic defect.
Show evidence (1 reference)
PMID:22896851 SUPPORT Human Clinical
"lower residual enzyme activities than subjects who were still alive at the time of reporting."
This supports reduced residual PDH complex activity as a key biochemical abnormality.
🔬

Clinical Trials

3
NCT02616484 PHASE_III ACTIVE_NOT_RECRUITING
Phase 3 trial of dichloroacetate in young children with pyruvate dehydrogenase complex deficiency, using a caregiver observer-reported outcome survey as the primary efficacy measure.
Target Phenotypes: Lactic acidosis ↗
Show evidence (1 reference)
clinicaltrials:NCT02616484 SUPPORT Human Clinical
"A novel Observer reported outcome (ObsRO) survey that is completed by study participant's parent/caregiver, is the efficacy outcome measure."
The trial record documents the efficacy outcome used in the Phase 3 DCA study.
NCT03734263 PHASE_II COMPLETED
Pilot clinical trial investigating safety and efficacy of phenylbutyrate therapy in patients with PDH complex deficiency.
Show evidence (1 reference)
clinicaltrials:NCT03734263 SUPPORT Human Clinical
"The aim of the study is to investigate the safety and efficacy of therapy."
The trial record identifies phenylbutyrate safety and efficacy as the study aim.
NCT03056794 NOT_APPLICABLE RECRUITING
Natural-history and advanced genetic study of children and adults with pyruvate dehydrogenase complex deficiencies.
Show evidence (1 reference)
clinicaltrials:NCT03056794 SUPPORT Human Clinical
"Children and adults with pyruvate dehydrogenase complex deficiency (PDCD) are participating in a research study seeking to better understand the genetic causes, symptoms, usefulness of current treatments, and outcomes for these disorders."
This trial record supports ongoing natural-history and genotype-outcome data collection.
{ }

Source YAML

click to show 
name: Pyruvate Dehydrogenase Deficiency
creation_date: "2026-05-05T20:20:53Z"
updated_date: "2026-05-21T14:56:54Z"
category: Mendelian
parents:
- mitochondrial disease
- inborn error of metabolism
synonyms:
- PDH
- PDHC
- Pyruvate dehydrogenase complex deficiency
description: >-
  Pyruvate dehydrogenase deficiency is a genetically heterogeneous mitochondrial
  neurometabolic disorder caused by defects in structural subunits or regulatory
  enzymes of the pyruvate dehydrogenase complex. Reduced PDH complex activity
  blocks oxidative decarboxylation of pyruvate to acetyl-CoA, causing pyruvate
  and lactate accumulation, lactic acidosis, impaired TCA-cycle substrate supply,
  and neurological disease that ranges from fatal neonatal lactic acidosis to
  later-onset ataxia, dystonia, seizures, and developmental delay.
disease_term:
  preferred_term: pyruvate dehydrogenase deficiency
  term:
    id: MONDO:0019169
    label: pyruvate dehydrogenase deficiency
prevalence:
- population: Europe
  percentage: "<1 / 1,000,000 point prevalence"
  notes: Orphanet classifies PDH deficiency as ultra-rare in Europe.
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<1 / 1 000 000 | Europe | Point prevalence | PMID:2015"
    explanation: Orphanet records point prevalence below 1 per 1,000,000 in Europe.
inheritance:
- name: X-linked dominant inheritance
  description: >-
    PDHA1-related E1-alpha deficiency is X-linked dominant, with affected males
    often presenting severely and females affected variably by X-inactivation.
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "X-linked dominant"
    explanation: Orphanet records X-linked dominant inheritance for the PDH deficiency spectrum.
  - reference: PMID:21908116
    reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic counseling is essential as PDHA1 deficiency (commonest defect) is X-linked although females can be affected due to unfavorable lyonization"
    explanation: This review supports the X-linked PDHA1 inheritance pattern and explains why females can be affected.
  - reference: PMID:38497591
    reference_title: Manifestations of X-linked pyruvate dehydrogenase complex deficiency in female PDHA1 carriers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pyruvate dehydrogenase complex deficiency is in up to 90% caused by pathogenic variants in the X-linked PDHA1 gene."
    explanation: This population-based PDHA1 carrier study supports PDHA1 as the dominant X-linked cause of PDH complex deficiency.
- name: Autosomal recessive inheritance
  description: >-
    Non-PDHA1 PDH complex structural-subunit, E3-binding-protein, and PDH
    phosphatase subtypes are inherited in autosomal recessive patterns.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for part of the PDH deficiency spectrum.
  - reference: PMID:21908116
    reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "while PDHB and PDH phosphatase (PDP) deficiencies (much rarer defects) are of autosomal recessive inheritance."
    explanation: This review identifies autosomal recessive inheritance for rarer non-PDHA1 subtypes.
progression:
- notes: >-
    The clinical spectrum is broad but severe disease usually presents in the
    first year of life with lactic acidosis, neurodevelopmental delay,
    structural brain lesions, and increased childhood mortality when residual
    enzyme activity is low and lactate levels are high.
  evidence:
  - reference: PMID:22896851
    reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting."
    explanation: The 371-patient review links earlier presentation, higher lactate, and lower residual enzyme activity with mortality.
has_subtypes:
- name: E1-alpha deficiency
  display_name: Pyruvate dehydrogenase E1-alpha deficiency
  subtype_term:
    preferred_term: pyruvate dehydrogenase E1-alpha deficiency
    term:
      id: MONDO:0010717
      label: pyruvate dehydrogenase E1-alpha deficiency
  description: >-
    The most frequent PDH deficiency subtype, typically caused by PDHA1 variants
    and associated with X-linked inheritance, lactic acidosis, neurodevelopmental
    impairment, hypotonia, seizures, and movement disorders.
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0010717
        label: pyruvate dehydrogenase E1-alpha deficiency
      mapping_predicate: skos:exactMatch
      mapping_source: Orphanet ORPHA:79243
      mapping_justification: Orphanet ORPHA:79243 lists MONDO:0010717 as an exact cross-reference.
  evidence:
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0010717 | Exact"
    explanation: Orphanet maps E1-alpha deficiency exactly to MONDO:0010717.
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDHA1 | pyruvate dehydrogenase E1 subunit alpha 1 | hgnc:8806 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies PDHA1 as a disease-causing gene for this subtype.
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "LONP1 | lon peptidase 1, mitochondrial | hgnc:9479 | Disease-causing germline mutation(s) in"
    explanation: Orphanet also lists LONP1 as a disease-causing gene in the E1-alpha subtype record.
- name: E1-beta deficiency
  display_name: Pyruvate dehydrogenase E1-beta deficiency
  subtype_term:
    preferred_term: pyruvate dehydrogenase E1-beta deficiency
    term:
      id: MONDO:0013580
      label: pyruvate dehydrogenase E1-beta deficiency
  description: >-
    A rare autosomal recessive PDH deficiency subtype caused by PDHB variants,
    classically associated with severe lactic acidosis, developmental delay, and
    hypotonia.
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0013580
        label: pyruvate dehydrogenase E1-beta deficiency
      mapping_predicate: skos:exactMatch
      mapping_source: Orphanet ORPHA:255138
      mapping_justification: Orphanet ORPHA:255138 lists MONDO:0013580 as an exact cross-reference.
  evidence:
  - reference: ORPHA:255138
    reference_title: "Pyruvate dehydrogenase E1-beta deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0013580 | Exact"
    explanation: Orphanet maps E1-beta deficiency exactly to MONDO:0013580.
  - reference: ORPHA:255138
    reference_title: "Pyruvate dehydrogenase E1-beta deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDHB | pyruvate dehydrogenase E1 subunit beta | hgnc:8808 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies PDHB as the disease-causing gene for this subtype.
- name: E2 deficiency
  display_name: Pyruvate dehydrogenase E2 deficiency
  subtype_term:
    preferred_term: pyruvate dehydrogenase E2 deficiency
    term:
      id: MONDO:0009502
      label: pyruvate dehydrogenase E2 deficiency
  description: >-
    A very rare PDH deficiency subtype caused by DLAT variants affecting the
    dihydrolipoamide S-acetyltransferase E2 component of the PDH complex.
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0009502
        label: pyruvate dehydrogenase E2 deficiency
      mapping_predicate: skos:exactMatch
      mapping_source: Orphanet ORPHA:79244
      mapping_justification: Orphanet ORPHA:79244 lists MONDO:0009502 as an exact cross-reference.
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0009502 | Exact"
    explanation: Orphanet maps E2 deficiency exactly to MONDO:0009502.
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "DLAT | dihydrolipoamide S-acetyltransferase | hgnc:2896 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies DLAT loss-of-function variants as disease-causing for this subtype.
- name: E3 deficiency
  display_name: Pyruvate dehydrogenase E3 deficiency
  subtype_term:
    preferred_term: pyruvate dehydrogenase E3 deficiency
    term:
      id: MONDO:0009529
      label: pyruvate dehydrogenase E3 deficiency
  description: >-
    DLD-related dihydrolipoamide dehydrogenase deficiency, which can present
    with PDH deficiency, branched-chain ketoacid dehydrogenase dysfunction,
    lactic acidosis, neurologic disease, and liver disease.
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0009529
        label: pyruvate dehydrogenase E3 deficiency
      mapping_predicate: skos:exactMatch
      mapping_source: Orphanet ORPHA:2394
      mapping_justification: Orphanet ORPHA:2394 lists MONDO:0009529 as an exact cross-reference.
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0009529 | Exact"
    explanation: Orphanet maps E3 deficiency exactly to MONDO:0009529.
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "DLD | dihydrolipoamide dehydrogenase | hgnc:2898 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies DLD loss-of-function variants as disease-causing for this subtype.
- name: E3-binding protein deficiency
  display_name: Pyruvate dehydrogenase E3-binding protein deficiency
  subtype_term:
    preferred_term: pyruvate dehydrogenase E3-binding protein deficiency
    term:
      id: MONDO:0009503
      label: pyruvate dehydrogenase E3-binding protein deficiency
  description: >-
    PDHX-related deficiency of the E3-binding protein/protein X component of
    the PDH complex, associated with variable lactic acidosis and neurologic
    dysfunction.
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0009503
        label: pyruvate dehydrogenase E3-binding protein deficiency
      mapping_predicate: skos:exactMatch
      mapping_source: Orphanet ORPHA:255182
      mapping_justification: Orphanet ORPHA:255182 lists MONDO:0009503 as an exact cross-reference.
  evidence:
  - reference: ORPHA:255182
    reference_title: "Pyruvate dehydrogenase E3-binding protein deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0009503 | Exact"
    explanation: Orphanet maps E3-binding protein deficiency exactly to MONDO:0009503.
  - reference: ORPHA:255182
    reference_title: "Pyruvate dehydrogenase E3-binding protein deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDHX | pyruvate dehydrogenase complex component X | hgnc:21350 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies PDHX as the disease-causing gene for this subtype.
- name: PDH phosphatase deficiency
  display_name: Pyruvate dehydrogenase phosphatase deficiency
  subtype_term:
    preferred_term: pyruvate dehydrogenase phosphatase deficiency
    term:
      id: MONDO:0012120
      label: pyruvate dehydrogenase phosphatase deficiency
  description: >-
    PDP1-related deficiency of pyruvate dehydrogenase phosphatase, impairing
    dephosphorylation and activation of the PDH complex.
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0012120
        label: pyruvate dehydrogenase phosphatase deficiency
      mapping_predicate: skos:exactMatch
      mapping_source: Orphanet ORPHA:79246
      mapping_justification: Orphanet ORPHA:79246 lists MONDO:0012120 as an exact cross-reference.
  evidence:
  - reference: ORPHA:79246
    reference_title: "Pyruvate dehydrogenase phosphatase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0012120 | Exact"
    explanation: Orphanet maps PDH phosphatase deficiency exactly to MONDO:0012120.
  - reference: ORPHA:79246
    reference_title: "Pyruvate dehydrogenase phosphatase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDP1 | pyruvate dehydrogenase phosphatase catalytic subunit 1 | hgnc:9279 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies PDP1 loss-of-function variants as disease-causing for this subtype.
pathophysiology:
- name: PDH complex component or phosphatase deficiency
  description: >-
    Pathogenic variants in PDH complex structural subunits or PDH phosphatase
    reduce PDH complex activity in the mitochondrial matrix. The canonical
    disease genes include PDHA1, PDHB, DLAT, DLD, PDHX, and PDP1.
  genes:
  - preferred_term: PDHA1
    term:
      id: hgnc:8806
      label: PDHA1
  - preferred_term: PDHB
    term:
      id: hgnc:8808
      label: PDHB
  - preferred_term: DLAT
    term:
      id: hgnc:2896
      label: DLAT
  - preferred_term: DLD
    term:
      id: hgnc:2898
      label: DLD
  - preferred_term: PDHX
    term:
      id: hgnc:21350
      label: PDHX
  - preferred_term: PDP1
    term:
      id: hgnc:9279
      label: PDP1
  molecular_functions:
  - preferred_term: pyruvate dehydrogenase activity
    term:
      id: GO:0004739
      label: pyruvate dehydrogenase (acetyl-transferring) activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:23622387
    reference_title: Disorders of pyruvate metabolism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pyruvate dehydrogenase has three main subunits, an additional E3-binding protein and two complex regulatory enzymes."
    explanation: This review identifies the PDH complex subunit and regulatory architecture underlying the recognized deficiency subtypes.
  - reference: PMID:23622387
    reference_title: Disorders of pyruvate metabolism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most frequent are deficiencies in PDH-E1α."
    explanation: The review identifies E1-alpha deficiency as the most frequent subtype.
  downstream:
  - target: Reduced pyruvate decarboxylation to acetyl-CoA
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21908116
      reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The pyruvate dehydrogenase complex (PDHc) is a mitochondrial matrix multienzyme complex that provides the link between glycolysis and the tricarboxylic acid (TCA) cycle by catalyzing the conversion of pyruvate into acetyl-CoA.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Decreased PDH complex activity
    causal_link_type: DIRECT
    description: Loss of PDH complex subunit or regulatory function is measured clinically as reduced PDH complex activity.
    evidence:
    - reference: ORPHA:255138
      reference_title: Pyruvate dehydrogenase E1-beta deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002928 | Decreased activity of the pyruvate dehydrogenase complex | Frequent (79-30%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: PDH complex enzyme activity
    causal_link_type: DIRECT
    description: The initiating molecular lesion lowers residual PDH complex enzyme activity.
    evidence:
    - reference: PMID:22896851
      reference_title: 'The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: lower residual enzyme activities than subjects who were still alive at the time of reporting.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: DLAT-associated E2 neurodegenerative movement-retinal syndrome
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: DLAT/E2 deficiency is a specific PDH complex subtype with retinal, neurodegenerative, movement, and basal-ganglia imaging findings.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A very rare form of pyruvate dehydrogenase deficiency (PDHD) characterized by variable lactic acidosis and neurological dysfunction, mainly appearing during childhood.
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: DLD-associated E3 hepatic and branched-chain ketoacid dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: DLD/E3 deficiency is a specific PDH complex subtype that can include hepatic disease and branched-chain amino-acid abnormalities.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Pyruvate dehydrogenase E3 deficiency is a very rare subtype of pyruvate dehydrogenase deficiency (PDHD) characterized by either early-onset lactic acidosis and delayed development, later-onset neurological dysfunction or liver disease.
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Abnormal facial shape
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Orphanet records craniofacial morphology as part of the PDH deficiency phenotype spectrum; the intermediate developmental mechanism is not resolved here.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001999 | Abnormal facial shape | Very frequent (99-80%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Frontal bossing
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002007 | Frontal bossing | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: High palate
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000218 | High palate | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Trigonocephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000243 | Trigonocephaly | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Narrow face
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000275 | Narrow face | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Epicanthus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000286 | Epicanthus | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Hypertelorism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000316 | Hypertelorism | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Long philtrum
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000343 | Long philtrum | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Wide nasal bridge
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000431 | Wide nasal bridge | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Upslanted palpebral fissure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Craniofacial morphology is linked to the primary genetic-metabolic disorder, with unresolved intermediate developmental mechanisms.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000582 | Upslanted palpebral fissure | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Pectus excavatum
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: This skeletal phenotype is recorded in the PDH deficiency spectrum, but the intermediate morphogenetic mechanism is not specified.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000767 | Pectus excavatum | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Multiple lipomas
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: This cutaneous phenotype is recorded in the PDH deficiency spectrum, but the intermediate mechanism is not specified.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001012 | Multiple lipomas | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Osteolytic defects of the middle phalanx of the 4th toe
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: This skeletal phenotype is recorded in the PDH deficiency spectrum, but the intermediate mechanism is not specified.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0100453 | Osteolytic defects of the middle phalanx of the 4th toe | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
- name: PDHA1 variant folding and assembly defects
  description: >-
    Many PDHA1 E1-alpha pathogenic variants impair folding, E1 incorporation,
    or assembly of the PDH complex, lowering overall PDC activity.
  genes:
  - preferred_term: PDHA1
    term:
      id: hgnc:8806
      label: PDHA1
  molecular_functions:
  - preferred_term: pyruvate dehydrogenase activity
    term:
      id: GO:0004739
      label: pyruvate dehydrogenase (acetyl-transferring) activity
    modifier: DECREASED
  evidence:
  - reference: PMID:29445841
    reference_title: Folding and assembly defects of pyruvate dehydrogenase deficiency-related variants in the E1α subunit of the pyruvate dehydrogenase complex.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our studies suggest that pathogenic E1α variants may be associated with structural changes of PDC and impaired folding of E1α."
    explanation: Yeast model and biochemical studies support variant-specific folding and assembly defects for PDHA1/E1-alpha.
  downstream:
  - target: Reduced pyruvate decarboxylation to acetyl-CoA
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29445841
      reference_title: Folding and assembly defects of pyruvate dehydrogenase deficiency-related variants in the E1α subunit of the pyruvate dehydrogenase complex.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Our studies suggest that pathogenic E1α variants may be associated with structural changes of PDC and impaired folding of E1α."
      explanation: Functional studies support PDHA1 variant folding and assembly defects as a direct route to impaired PDC activity and reduced pyruvate oxidation.
- name: LONP1 impaired phospho-E1-alpha proteolysis
  description: >-
    Biallelic pathogenic LONP1 variants can impair mitochondrial LonP1 protease
    degradation of phosphorylated PDH E1-alpha. Accumulation of inhibitory
    phospho-E1-alpha reduces PDH activity and produces a PDH deficiency
    biochemical phenotype.
  genes:
  - preferred_term: LONP1
    term:
      id: hgnc:9479
      label: LONP1
  biological_processes:
  - preferred_term: mitochondrial phospho-E1-alpha proteolysis
    term:
      id: GO:0006508
      label: proteolysis
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:30304514
    reference_title: "Bi-allelic mutations of LONP1 encoding the mitochondrial LonP1 protease cause pyruvate dehydrogenase deficiency and profound neurodegeneration with progressive cerebellar atrophy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We demonstrated that in the siblings' fibroblasts, PDH dysfunction was caused by increased levels of the phosphorylated E1α subunit of PDH, which inhibits enzyme activity."
    explanation: Patient-derived fibroblast experiments connect LONP1 variant cells to inhibitory phospho-E1-alpha accumulation and PDH dysfunction.
  - reference: PMID:30304514
    reference_title: "Bi-allelic mutations of LONP1 encoding the mitochondrial LonP1 protease cause pyruvate dehydrogenase deficiency and profound neurodegeneration with progressive cerebellar atrophy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, in vitro studies demonstrated that purified LonP1-P761L failed to degrade phosphorylated E1α, in contrast to wild-type LonP1."
    explanation: Biochemical evidence supports the specific loss of LonP1-mediated phospho-E1-alpha proteolysis.
  downstream:
  - target: Reduced pyruvate decarboxylation to acetyl-CoA
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Failed LonP1 degradation of phosphorylated E1-alpha increases the inhibitory phosphorylated E1-alpha pool, lowering PDH activity and pyruvate oxidation.
    evidence:
    - reference: PMID:30304514
      reference_title: "Bi-allelic mutations of LONP1 encoding the mitochondrial LonP1 protease cause pyruvate dehydrogenase deficiency and profound neurodegeneration with progressive cerebellar atrophy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "PDH dysfunction was caused by increased levels of the phosphorylated E1α subunit of PDH, which inhibits enzyme activity."
      explanation: Patient-derived fibroblast evidence supports inhibitory phospho-E1-alpha accumulation as the intermediate lowering PDH activity and pyruvate oxidation.
  - target: Decreased PDH complex activity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Patient fibroblasts with biallelic LONP1 variants showed reduced PDH activity through inhibitory E1-alpha phosphorylation.
    evidence:
    - reference: PMID:30304514
      reference_title: "Bi-allelic mutations of LONP1 encoding the mitochondrial LonP1 protease cause pyruvate dehydrogenase deficiency and profound neurodegeneration with progressive cerebellar atrophy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "the siblings' fibroblasts had reduced pyruvate dehydrogenase (PDH) activity"
      explanation: Patient-derived fibroblast evidence directly supports decreased PDH activity downstream of biallelic LONP1 dysfunction.
- name: Thiamine-responsive PDHA1 residual activity
  description: >-
    Selected PDHA1 variants can retain thiamine-responsive residual activity,
    producing milder movement-disorder presentations that may improve with
    high-dose thiamine rather than representing broad responsiveness of all PDH
    complex subtypes.
  genes:
  - preferred_term: PDHA1
    term:
      id: hgnc:8806
      label: PDHA1
  molecular_functions:
  - preferred_term: pyruvate dehydrogenase activity
    term:
      id: GO:0004739
      label: pyruvate dehydrogenase (acetyl-transferring) activity
    modifier: DECREASED
  evidence:
  - reference: PMID:26008863
    reference_title: Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PDH deficiency caused by a Leu216Ser mutation in PDHA1."
    explanation: This case identifies a PDHA1 variant in a thiamine-responsive PDH deficiency presentation.
  - reference: PMID:26008863
    reference_title: Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia completely remitted after high doses of thiamine, remaining free of symptoms after 3 years of follow up."
    explanation: The same case supports thiamine responsiveness in a selected PDHA1 presentation.
  downstream:
  - target: Reduced pyruvate decarboxylation to acetyl-CoA
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26008863
      reference_title: Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PDH deficiency caused by a Leu216Ser mutation in PDHA1."
      explanation: This supports reduced PDH function in a selected thiamine-responsive PDHA1 variant branch.
- name: Reduced pyruvate decarboxylation to acetyl-CoA
  description: >-
    PDH complex deficiency blocks oxidative decarboxylation of pyruvate to
    acetyl-CoA, weakening the link between glycolysis and the TCA cycle.
  biological_processes:
  - preferred_term: pyruvate decarboxylation to acetyl-CoA
    term:
      id: GO:0006086
      label: pyruvate decarboxylation to acetyl-CoA
    modifier: DECREASED
  - preferred_term: tricarboxylic acid cycle
    term:
      id: GO:0006099
      label: tricarboxylic acid cycle
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:21908116
    reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pyruvate dehydrogenase complex (PDHc) is a mitochondrial matrix multienzyme complex that provides the link between glycolysis and the tricarboxylic acid (TCA) cycle by catalyzing the conversion of pyruvate into acetyl-CoA."
    explanation: This directly supports the PDH complex step that is deficient in the disorder.
  - reference: PMID:23467562
    reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Pyruvate dehydrogenase complex (PDHC), an enzyme complex that catalyzes the irreversible conversion of pyruvate into acetyl-CoA (coenzyme A), plays a central role in linking glycolysis to the tricarboxylic acid (TCA) cycle and lipogenic pathways"
    explanation: This mechanistic review establishes PDHC as the pyruvate-to-acetyl-CoA link whose activity is deficient.
  downstream:
  - target: Lactate and pyruvate accumulation
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22896851
      reference_title: 'The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Although the clinical spectrum of PDC deficiency is broad, the dominant clinical phenotype includes presentation during the first year of life; neurological and neuromuscular degeneration; structural lesions revealed by neuroimaging; lactic acidosis and a blood lactate:pyruvate ratio ≤ 20.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Cerebral energy failure and neurodevelopmental injury
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21908116
      reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In severe deficiency states the resulting energy deficit impacts on brain development in utero resulting in structural brain anomalies and epilepsy.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
- name: PDK-regulated residual PDH activity
  description: >-
    Residual PDH complex activity is modulated by phosphorylation of E1-alpha by
    pyruvate dehydrogenase kinases and dephosphorylation by PDH phosphatases,
    making kinase inhibition a plausible treatment target in selected variants.
  genes:
  - preferred_term: PDHA1
    term:
      id: hgnc:8806
      label: PDHA1
  biological_processes:
  - preferred_term: pyruvate decarboxylation to acetyl-CoA
    term:
      id: GO:0006086
      label: pyruvate decarboxylation to acetyl-CoA
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:23467562
    reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Phosphorylation of specific serine residues of the E1α subunit of PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC activity."
    explanation: This supports phosphorylation state as a regulator of residual PDH complex activity.
  downstream:
  - target: Reduced pyruvate decarboxylation to acetyl-CoA
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:23467562
      reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Phosphorylation of specific serine residues of the E1α subunit of PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC activity."
      explanation: This supports PDK-regulated phosphorylation as a direct modulator of active PDH complex and pyruvate oxidation.
- name: Lactate and pyruvate accumulation
  description: >-
    When pyruvate cannot efficiently enter the PDH complex reaction, pyruvate
    and lactate accumulate in blood, CSF, and tissues, producing the classic
    biochemical pattern of lactic acidosis with a lactate:pyruvate ratio often
    not exceeding 20.
  biological_processes:
  - preferred_term: pyruvate metabolic process
    term:
      id: GO:0006090
      label: pyruvate metabolic process
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:22896851
    reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although the clinical spectrum of PDC deficiency is broad, the dominant clinical phenotype includes presentation during the first year of life; neurological and neuromuscular degeneration; structural lesions revealed by neuroimaging; lactic acidosis and a blood lactate:pyruvate ratio ≤ 20."
    explanation: The cohort review directly supports lactic acidosis and the characteristic lactate:pyruvate ratio pattern.
  - reference: PMID:23467562
    reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A deficiency of any enzyme in these pathways results in inadequate removal of pyruvate and lactate from blood and tissues and causes lactic acidosis."
    explanation: The mechanistic review explains pyruvate and lactate accumulation downstream of impaired pyruvate oxidation.
  downstream:
  - target: Congenital lactic acidosis
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Manifestations range from often fatal, severe, neonatal lactic acidosis to later-onset neurological disorders.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Lactate
    causal_link_type: DIRECT
    description: Impaired pyruvate oxidation increases lactate in blood and CSF.
    evidence:
    - reference: PMID:22896851
      reference_title: 'The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Pyruvate
    causal_link_type: DIRECT
    description: Blocked PDH flux leaves pyruvate insufficiently cleared.
    evidence:
    - reference: PMID:23467562
      reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A deficiency of any enzyme in these pathways results in inadequate removal of pyruvate and lactate from blood and tissues and causes lactic acidosis.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Increased circulating lactate
    causal_link_type: DIRECT
    description: Lactate accumulation appears clinically as increased circulating lactate concentration.
    evidence:
    - reference: ORPHA:79243
      reference_title: Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002151 | Increased circulating lactate concentration | Very frequent (99-80%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Increased serum pyruvate
    causal_link_type: DIRECT
    description: Pyruvate accumulation appears clinically as increased circulating pyruvate concentration.
    evidence:
    - reference: ORPHA:79243
      reference_title: Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0003542 | Increased serum pyruvate | Frequent (79-30%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
- name: Cerebral energy failure and neurodevelopmental injury
  description: >-
    Reduced acetyl-CoA delivery to the TCA cycle and mitochondrial energy
    production injures the developing brain, contributing to structural brain
    anomalies, seizures, hypotonia, ataxia, and developmental delay.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:21908116
    reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In severe deficiency states the resulting energy deficit impacts on brain development in utero resulting in structural brain anomalies and epilepsy."
    explanation: This review links PDH-deficiency energy failure to brain maldevelopment and epilepsy.
  - reference: PMID:21908116
    reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epileptogenesis in PDHc deficiency is linked to energy failure, development of structural brain anomalies and abnormal neurotransmitter metabolism."
    explanation: This supports seizures as a downstream consequence of cerebral energy failure and abnormal neurotransmitter metabolism.
  downstream:
  - target: Neurodevelopmental delay and hypotonia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22896851
      reference_title: 'The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Seizures and movement disorders
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21908116
      reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Milder deficiency states present with variable manifestations that include cognitive delay, ataxia, and seizures.
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Aplasia/Hypoplasia of the corpus callosum
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Energy failure in brain development is associated with structural brain malformations, including corpus-callosum dysgenesis.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0007370 | Aplasia/Hypoplasia of the corpus callosum | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Ventriculomegaly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Structural brain abnormalities in PDH complex deficiency include ventriculomegaly.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002119 | Ventriculomegaly | Occasional (29-5%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Neurodegeneration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Chronic cerebral energy failure contributes to progressive neurological degeneration.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002180 | Neurodegeneration | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Microcephaly is linked to the neurodevelopmental injury spectrum, with intermediate growth mechanisms not resolved here.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000252 | Microcephaly | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
- name: Congenital lactic acidosis
  description: >-
    Lactate accumulation causes congenital or early-onset lactic acidosis, often
    severe in neonatal presentations and associated with respiratory compensation
    such as tachypnea.
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Manifestations range from often fatal, severe, neonatal lactic acidosis to later-onset neurological disorders."
    explanation: Orphanet identifies severe neonatal lactic acidosis as a key manifestation.
  downstream:
  - target: Lactic acidosis
    causal_link_type: DIRECT
    description: Congenital lactic acidosis is the clinical manifestation of lactate accumulation.
    evidence:
    - reference: PMID:22896851
      reference_title: 'The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: lactic acidosis and a blood lactate:pyruvate ratio ≤ 20
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Tachypnea
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Tachypnea can reflect respiratory compensation during metabolic acidosis.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002789 | Tachypnea | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Dyspnea
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Dyspnea is recorded in the PDH deficiency phenotype spectrum and can accompany severe metabolic decompensation.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002094 | Dyspnea | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Lethargy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Metabolic decompensation from lactic acidosis contributes to lethargy.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001254 | Lethargy | Very frequent (99-80%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Feeding difficulties in infancy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Feeding difficulty is part of the early severe presentation; the immediate intermediate is not resolved in this graph.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0008872 | Feeding difficulties in infancy | Very frequent (99-80%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Vomiting
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Vomiting is recorded in the E3 deficiency metabolic-decompensation phenotype spectrum.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002013 | Vomiting | Very frequent (99-80%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Hypoglycemia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hypoglycemia is recorded in E3 deficiency and grouped here with metabolic decompensation features.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001943 | Hypoglycemia | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
- name: Neurodevelopmental delay and hypotonia
  description: >-
    Neurodevelopmental delay and hypotonia are among the most common clinical
    signs in the 371-patient PDC deficiency spectrum.
  evidence:
  - reference: PMID:22896851
    reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency."
    explanation: The large review directly identifies neurodevelopmental delay and hypotonia as the commonest signs.
  downstream:
  - target: Hypotonia
    causal_link_type: DIRECT
    description: Hypotonia is one of the commonest signs in the PDC deficiency spectrum.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001252 | Hypotonia | Very frequent (99-80%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Global developmental delay
    causal_link_type: DIRECT
    description: Global developmental delay is the clinical phenotype captured by this neurodevelopmental injury node.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001263 | Global developmental delay | Frequent (79-30%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Cerebral palsy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: PDH deficiency can resemble nonprogressive cerebral palsy, especially in female PDHA1 deficiency.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0100021 | Cerebral palsy | Occasional (29-5%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Growth delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Growth delay is part of the broader developmental phenotype spectrum.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001510 | Growth delay | Very frequent (99-80%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Intrauterine growth retardation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Intrauterine growth restriction is part of the broader developmental phenotype spectrum.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001511 | Intrauterine growth retardation | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
- name: Seizures and movement disorders
  description: >-
    Severe and milder PDH deficiency states can produce seizures, ataxia,
    dystonia, and other movement disorders through energy failure, structural
    brain anomalies, and neurotransmitter disturbance.
  evidence:
  - reference: PMID:21908116
    reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Milder deficiency states present with variable manifestations that include cognitive delay, ataxia, and seizures."
    explanation: This supports ataxia and seizures in milder PDH deficiency.
  - reference: PMID:26008863
    reference_title: Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia precipitated by exercise may be the only symptom of a PDH deficiency"
    explanation: This case report and mini-review support dystonia as part of the PDH deficiency spectrum.
  downstream:
  - target: Seizure
    causal_link_type: DIRECT
    description: Seizures are a core manifestation of PDH-related cerebral energy failure.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001250 | Seizure | Frequent (79-30%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Ataxia
    causal_link_type: DIRECT
    description: Milder PDH deficiency states can include ataxia.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001251 | Ataxia | Frequent (79-30%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Spasticity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Spasticity is a pyramidal motor manifestation within the PDH neurologic phenotype spectrum.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001257 | Spasticity | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Dysarthria
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Dysarthria is grouped with PDH-related movement and motor-control dysfunction.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001260 | Dysarthria | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Choreoathetosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Choreoathetosis is grouped with PDH-related movement disorder manifestations.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001266 | Choreoathetosis | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Gait disturbance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Gait disturbance follows from ataxic, dystonic, or pyramidal motor involvement.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001288 | Gait disturbance | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Dystonia
    causal_link_type: DIRECT
    description: Dystonia is directly supported as a PDH deficiency manifestation.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001332 | Dystonia | Occasional (29-5%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Tremor
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Tremor is grouped with the movement-disorder manifestations of PDH deficiency.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001337 | Tremor | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Abnormal pyramidal sign
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Pyramidal signs reflect motor pathway involvement in the PDH neurologic phenotype.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0007256 | Abnormal pyramidal sign | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Abnormality of eye movement
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Abnormal eye movements are grouped with the neurologic movement-control phenotype.
    evidence:
    - reference: ORPHA:765
      reference_title: Pyruvate dehydrogenase deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000496 | Abnormality of eye movement | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Paroxysmal dystonia
    causal_link_type: DIRECT
    description: Paroxysmal dystonia is a subtype-specific dystonic manifestation.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002268 | Paroxysmal dystonia | Frequent (79-30%)
      explanation: This evidence supports the target as a direct PDH-deficiency consequence represented by the edge.
  - target: Broad-based gait
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Broad-based gait is a subtype-specific gait manifestation linked to movement-system involvement.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002136 | Broad-based gait | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Lower limb hyperreflexia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Lower-limb hyperreflexia is grouped with pyramidal motor involvement.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002395 | Lower limb hyperreflexia | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Atypical behavior
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Atypical behavior is grouped with neurologic involvement, with intermediate neurobehavioral mechanisms not resolved here.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000708 | Atypical behavior | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
- name: DLAT-associated E2 neurodegenerative movement-retinal syndrome
  description: >-
    The DLAT/E2 subtype is characterized by childhood lactic acidosis and
    neurological dysfunction, with Orphanet phenotype rows documenting retinal
    degeneration, neurodegeneration, paroxysmal dystonia, broad-based gait,
    lower-limb hyperreflexia, globus-pallidus imaging abnormalities, atypical
    behavior, and low circulating vitamin B1.
  genes:
  - preferred_term: DLAT
    term:
      id: hgnc:2896
      label: DLAT
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A very rare form of pyruvate dehydrogenase deficiency (PDHD) characterized by variable lactic acidosis and neurological dysfunction, mainly appearing during childhood."
    explanation: Orphanet defines E2 deficiency as a childhood PDH deficiency subtype with lactic acidosis and neurologic dysfunction.
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "DLAT | dihydrolipoamide S-acetyltransferase | hgnc:2896 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies DLAT loss-of-function variants as causal for the E2 subtype.
  downstream:
  - target: Retinal degeneration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Retinal degeneration is an E2-deficiency neurologic sensory phenotype.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000546 | Retinal degeneration | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Neurodegeneration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Neurodegeneration is recorded as a frequent E2-deficiency manifestation.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002180 | Neurodegeneration | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Paroxysmal dystonia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Paroxysmal dystonia is recorded as a frequent E2-deficiency movement phenotype.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002268 | Paroxysmal dystonia | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Broad-based gait
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Broad-based gait is recorded as a frequent E2-deficiency gait phenotype.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002136 | Broad-based gait | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Lower limb hyperreflexia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Lower-limb hyperreflexia is recorded as a frequent E2-deficiency pyramidal sign.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002395 | Lower limb hyperreflexia | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Eye of the tiger anomaly of globus pallidus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: This globus-pallidus imaging sign is recorded in E2 deficiency.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002454 | Eye of the tiger anomaly of globus pallidus | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Atypical behavior
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Atypical behavior is recorded in E2 deficiency, with intermediate neurobehavioral mechanisms not resolved here.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0000708 | Atypical behavior | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Low levels of vitamin B1
    causal_link_type: UNKNOWN
    description: Low vitamin B1 is recorded in the E2 deficiency phenotype table; its mechanistic role is not resolved here.
    evidence:
    - reference: ORPHA:79244
      reference_title: Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0100503 | Low levels of vitamin B1 | Very frequent (99-80%)
      explanation: This evidence supports the target association, while the causal role remains unresolved.
- name: DLD-associated E3 hepatic and branched-chain ketoacid dysfunction
  description: >-
    The DLD/E3 subtype can present with early lactic acidosis, delayed
    development, later neurologic dysfunction, or liver disease, and Orphanet
    synonymizes it with E3-deficient maple syrup urine disease. This captures
    the E3-subtype hepatic and branched-chain amino-acid phenotype branch.
  genes:
  - preferred_term: DLD
    term:
      id: hgnc:2898
      label: DLD
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Pyruvate dehydrogenase E3 deficiency is a very rare subtype of pyruvate dehydrogenase deficiency (PDHD) characterized by either early-onset lactic acidosis and delayed development, later-onset neurological dysfunction or liver disease."
    explanation: Orphanet defines E3 deficiency as a PDH deficiency subtype with lactic acidosis, developmental delay, neurologic dysfunction, or liver disease.
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "E3-deficient maple syrup urine disease"
    explanation: The synonym supports the E3 subtype's overlap with branched-chain ketoacid dehydrogenase dysfunction.
  downstream:
  - target: Hepatic failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hepatic failure is an E3-deficiency systemic manifestation of DLD-related disease.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001399 | Hepatic failure | Occasional (29-5%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Hypoglycemia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hypoglycemia is recorded in E3 deficiency and grouped with metabolic decompensation features.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0001943 | Hypoglycemia | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Vomiting
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Vomiting is recorded in the E3 deficiency metabolic-decompensation phenotype spectrum.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002013 | Vomiting | Very frequent (99-80%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Hepatomegaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hepatomegaly is an E3-deficiency systemic manifestation of DLD-related disease.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002240 | Hepatomegaly | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Hepatic encephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hepatic encephalopathy is an E3-deficiency systemic manifestation of DLD-related disease.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002480 | Hepatic encephalopathy | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Elevated circulating hepatic transaminase concentration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Elevated transaminases are an E3-deficiency hepatic biochemical manifestation.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0002910 | Elevated circulating hepatic transaminase concentration | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
  - target: Elevated plasma branched chain amino acids
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: DLD/E3 deficiency overlaps with E3-deficient maple syrup urine disease, producing branched-chain amino acid abnormalities.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0008344 | Elevated plasma branched chain amino acids | Frequent (79-30%)
      explanation: This evidence supports the target association; the edge uses the known intermediate relationship described in the upstream mechanism.
  - target: Hypercoagulability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hypercoagulability is recorded in E3 deficiency, with intermediate mechanisms not resolved here.
    evidence:
    - reference: ORPHA:2394
      reference_title: Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HP:0100724 | Hypercoagulability | Frequent (79-30%)
      explanation: This evidence supports the target phenotype association; the edge remains indirect because intervening mechanisms are not resolved.
phenotypes:
- category: Biochemical
  name: Lactic acidosis
  description: >-
    Lactic acidosis is a core biochemical and clinical manifestation of PDH
    deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Lactic acidosis
    term:
      id: HP:0003128
      label: Lactic acidosis
  evidence:
  - reference: PMID:22896851
    reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lactic acidosis and a blood lactate:pyruvate ratio ≤ 20"
    explanation: The cohort review supports lactic acidosis as part of the dominant PDH deficiency phenotype.
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003128 | Lactic acidosis | Frequent (79-30%)"
    explanation: Orphanet provides frequency support for lactic acidosis in the E1-alpha subtype.
- category: Biochemical
  name: Increased circulating lactate
  description: Blood lactate is commonly elevated in PDH deficiency.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Increased circulating lactate concentration
    term:
      id: HP:0002151
      label: Increased circulating lactate concentration
  evidence:
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002151 | Increased circulating lactate concentration | Very frequent (99-80%)"
    explanation: Orphanet provides structured frequency support for increased circulating lactate in E1-alpha deficiency.
- category: Biochemical
  name: Increased serum pyruvate
  description: Blood pyruvate can be elevated because pyruvate oxidation is blocked.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Increased circulating pyruvate concentration
    term:
      id: HP:0003542
      label: Increased circulating pyruvate concentration
  evidence:
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003542 | Increased serum pyruvate | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for increased serum pyruvate in E1-alpha deficiency.
- category: Biochemical
  name: Decreased PDH complex activity
  description: Reduced PDH complex activity is the defining enzymatic abnormality.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Decreased activity of the pyruvate dehydrogenase complex
    term:
      id: HP:0002928
      label: Decreased activity of the pyruvate dehydrogenase complex
  evidence:
  - reference: ORPHA:255138
    reference_title: "Pyruvate dehydrogenase E1-beta deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002928 | Decreased activity of the pyruvate dehydrogenase complex | Frequent (79-30%)"
    explanation: Orphanet provides structured support for decreased PDH complex activity.
- category: Neurological
  name: Hypotonia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Very frequent (99-80%)"
    explanation: Orphanet provides structured frequency support for hypotonia.
- category: Neurological
  name: Seizure
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for seizures.
- category: Neurological
  name: Global developmental delay
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for global developmental delay.
- category: Neurological
  name: Ataxia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001251 | Ataxia | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for ataxia.
- category: Neurological
  name: Spasticity
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001257 | Spasticity | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for spasticity.
- category: Neurological
  name: Dysarthria
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001260 | Dysarthria | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for dysarthria.
- category: Neurological
  name: Choreoathetosis
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001266 | Choreoathetosis | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for choreoathetosis.
- category: Neurological
  name: Gait disturbance
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for gait disturbance.
- category: Neurological
  name: Dystonia
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001332 | Dystonia | Occasional (29-5%)"
    explanation: Orphanet provides structured frequency support for dystonia.
- category: Neurological
  name: Tremor
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001337 | Tremor | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for tremor.
- category: Neurological
  name: Lethargy
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001254 | Lethargy | Very frequent (99-80%)"
    explanation: Orphanet provides structured frequency support for lethargy.
- category: Neurological
  name: Abnormal pyramidal sign
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormal pyramidal sign
    term:
      id: HP:0007256
      label: Abnormal pyramidal sign
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007256 | Abnormal pyramidal sign | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for pyramidal signs.
- category: Neurological
  name: Cerebral palsy
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Cerebral palsy
    term:
      id: HP:0100021
      label: Cerebral palsy
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100021 | Cerebral palsy | Occasional (29-5%)"
    explanation: Orphanet provides structured frequency support for cerebral-palsy-like presentation.
- category: Neuroimaging
  name: Aplasia/Hypoplasia of the corpus callosum
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Aplasia/Hypoplasia of the corpus callosum
    term:
      id: HP:0007370
      label: Aplasia/Hypoplasia of the corpus callosum
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007370 | Aplasia/Hypoplasia of the corpus callosum | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for corpus-callosum aplasia/hypoplasia.
- category: Neuroimaging
  name: Ventriculomegaly
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002119 | Ventriculomegaly | Occasional (29-5%)"
    explanation: Orphanet provides structured support for ventriculomegaly.
- category: Growth
  name: Growth delay
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001510 | Growth delay | Very frequent (99-80%)"
    explanation: Orphanet provides structured frequency support for growth delay.
- category: Growth
  name: Intrauterine growth retardation
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001511 | Intrauterine growth retardation | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for intrauterine growth restriction.
- category: Feeding
  name: Feeding difficulties in infancy
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Feeding difficulties in infancy
    term:
      id: HP:0008872
      label: Feeding difficulties in infancy
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008872 | Feeding difficulties in infancy | Very frequent (99-80%)"
    explanation: Orphanet provides structured frequency support for infant feeding difficulties.
- category: Respiratory
  name: Tachypnea
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Tachypnea
    term:
      id: HP:0002789
      label: Tachypnea
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002789 | Tachypnea | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for tachypnea.
- category: Respiratory
  name: Dyspnea
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002094 | Dyspnea | Occasional (29-5%)"
    explanation: Orphanet provides structured frequency support for dyspnea.
- category: Craniofacial
  name: Abnormal facial shape
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001999 | Abnormal facial shape | Very frequent (99-80%)"
    explanation: Orphanet provides structured frequency support for abnormal facial shape.
- category: Craniofacial
  name: Microcephaly
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000252 | Microcephaly | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for microcephaly.
- category: Craniofacial
  name: Frontal bossing
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002007 | Frontal bossing | Occasional (29-5%)"
    explanation: Orphanet provides structured support for frontal bossing.
- category: Craniofacial
  name: High palate
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: High palate
    term:
      id: HP:0000218
      label: High palate
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000218 | High palate | Occasional (29-5%)"
    explanation: Orphanet provides structured support for high palate.
- category: Craniofacial
  name: Trigonocephaly
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Trigonocephaly
    term:
      id: HP:0000243
      label: Trigonocephaly
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000243 | Trigonocephaly | Occasional (29-5%)"
    explanation: Orphanet provides structured support for trigonocephaly.
- category: Craniofacial
  name: Narrow face
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Narrow face
    term:
      id: HP:0000275
      label: Narrow face
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000275 | Narrow face | Occasional (29-5%)"
    explanation: Orphanet provides structured support for narrow face.
- category: Craniofacial
  name: Epicanthus
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Epicanthus
    term:
      id: HP:0000286
      label: Epicanthus
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000286 | Epicanthus | Occasional (29-5%)"
    explanation: Orphanet provides structured support for epicanthus.
- category: Craniofacial
  name: Hypertelorism
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000316 | Hypertelorism | Occasional (29-5%)"
    explanation: Orphanet provides structured support for hypertelorism.
- category: Craniofacial
  name: Long philtrum
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Long philtrum
    term:
      id: HP:0000343
      label: Long philtrum
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000343 | Long philtrum | Occasional (29-5%)"
    explanation: Orphanet provides structured support for long philtrum.
- category: Craniofacial
  name: Wide nasal bridge
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Wide nasal bridge
    term:
      id: HP:0000431
      label: Wide nasal bridge
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000431 | Wide nasal bridge | Occasional (29-5%)"
    explanation: Orphanet provides structured support for wide nasal bridge.
- category: Craniofacial
  name: Upslanted palpebral fissure
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Upslanted palpebral fissure
    term:
      id: HP:0000582
      label: Upslanted palpebral fissure
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000582 | Upslanted palpebral fissure | Occasional (29-5%)"
    explanation: Orphanet provides structured support for upslanted palpebral fissures.
- category: Ophthalmologic
  name: Abnormality of eye movement
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormality of eye movement
    term:
      id: HP:0000496
      label: Abnormality of eye movement
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000496 | Abnormality of eye movement | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for abnormal eye movements.
- category: Musculoskeletal
  name: Pectus excavatum
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000767 | Pectus excavatum | Occasional (29-5%)"
    explanation: Orphanet provides structured support for pectus excavatum.
- category: Dermatologic
  name: Multiple lipomas
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Multiple lipomas
    term:
      id: HP:0001012
      label: Multiple lipomas
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001012 | Multiple lipomas | Occasional (29-5%)"
    explanation: Orphanet provides structured support for multiple lipomas.
- category: Musculoskeletal
  name: Osteolytic defects of the middle phalanx of the 4th toe
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Osteolytic defects of the middle phalanx of the 4th toe
    term:
      id: HP:0100453
      label: Osteolytic defects of the middle phalanx of the 4th toe
  evidence:
  - reference: ORPHA:765
    reference_title: "Pyruvate dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100453 | Osteolytic defects of the middle phalanx of the 4th toe | Frequent (79-30%)"
    explanation: Orphanet provides structured frequency support for this skeletal finding.
- category: Ophthalmologic
  name: Retinal degeneration
  subtype: E2 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Retinal degeneration
    term:
      id: HP:0000546
      label: Retinal degeneration
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000546 | Retinal degeneration | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for retinal degeneration in E2 deficiency.
- category: Neurological
  name: Neurodegeneration
  subtype: E2 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Neurodegeneration
    term:
      id: HP:0002180
      label: Neurodegeneration
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002180 | Neurodegeneration | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for neurodegeneration in E2 deficiency.
- category: Neurological
  name: Paroxysmal dystonia
  subtype: E2 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Paroxysmal dystonia
    term:
      id: HP:0002268
      label: Paroxysmal dystonia
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002268 | Paroxysmal dystonia | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for paroxysmal dystonia in E2 deficiency.
- category: Neurological
  name: Broad-based gait
  subtype: E2 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Broad-based gait
    term:
      id: HP:0002136
      label: Broad-based gait
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002136 | Broad-based gait | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for broad-based gait in E2 deficiency.
- category: Neurological
  name: Lower limb hyperreflexia
  subtype: E2 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Lower limb hyperreflexia
    term:
      id: HP:0002395
      label: Lower limb hyperreflexia
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002395 | Lower limb hyperreflexia | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for lower limb hyperreflexia in E2 deficiency.
- category: Neuroimaging
  name: Eye of the tiger anomaly of globus pallidus
  subtype: E2 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Eye of the tiger anomaly of globus pallidus
    term:
      id: HP:0002454
      label: Eye of the tiger anomaly of globus pallidus
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002454 | Eye of the tiger anomaly of globus pallidus | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for this E2-deficiency neuroimaging feature.
- category: Neurological
  name: Atypical behavior
  subtype: E2 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000708 | Atypical behavior | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for atypical behavior in E2 deficiency.
- category: Biochemical
  name: Low levels of vitamin B1
  subtype: E2 deficiency
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Low levels of vitamin B1
    term:
      id: HP:0100503
      label: Decreased circulating vitamin B1 concentration
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100503 | Low levels of vitamin B1 | Very frequent (99-80%)"
    explanation: Orphanet provides subtype-specific frequency support for low vitamin B1 levels in E2 deficiency.
- category: Hepatic
  name: Hepatic failure
  subtype: E3 deficiency
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001399 | Hepatic failure | Occasional (29-5%)"
    explanation: Orphanet provides subtype-specific support for hepatic failure in E3 deficiency.
- category: Biochemical
  name: Hypoglycemia
  subtype: E3 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypoglycemia
    term:
      id: HP:0001943
      label: Hypoglycemia
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001943 | Hypoglycemia | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for hypoglycemia in E3 deficiency.
- category: Gastrointestinal
  name: Vomiting
  subtype: E3 deficiency
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002013 | Vomiting | Very frequent (99-80%)"
    explanation: Orphanet provides subtype-specific frequency support for vomiting in E3 deficiency.
- category: Hepatic
  name: Hepatomegaly
  subtype: E3 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002240 | Hepatomegaly | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for hepatomegaly in E3 deficiency.
- category: Hepatic
  name: Hepatic encephalopathy
  subtype: E3 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatic encephalopathy
    term:
      id: HP:0002480
      label: Hepatic encephalopathy
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002480 | Hepatic encephalopathy | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for hepatic encephalopathy in E3 deficiency.
- category: Biochemical
  name: Elevated circulating hepatic transaminase concentration
  subtype: E3 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002910 | Elevated circulating hepatic transaminase concentration | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for transaminase elevation in E3 deficiency.
- category: Biochemical
  name: Elevated plasma branched chain amino acids
  subtype: E3 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Elevated plasma branched chain amino acids
    term:
      id: HP:0008344
      label: Elevated circulating branched chain amino acid concentration
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008344 | Elevated plasma branched chain amino acids | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for elevated branched-chain amino acids in E3 deficiency.
- category: Hematologic
  name: Hypercoagulability
  subtype: E3 deficiency
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypercoagulability
    term:
      id: HP:0100724
      label: Hypercoagulability
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100724 | Hypercoagulability | Frequent (79-30%)"
    explanation: Orphanet provides subtype-specific frequency support for hypercoagulability in E3 deficiency.
biochemical:
- name: Lactate
  presence: INCREASED
  context: Blood and CSF lactate are often elevated in PDH deficiency.
  readouts:
  - target: Lactate and pyruvate accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated blood or CSF lactate reports the lactate arm of pyruvate-to-lactate accumulation downstream of impaired PDH flux.
    evidence:
    - reference: PMID:22896851
      reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting."
      explanation: The cohort review supports blood lactate as a measurable biochemical abnormality associated with PDH deficiency severity.
  evidence:
  - reference: PMID:22896851
    reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting."
    explanation: The clinical review supports elevated lactate as a disease-severity and mortality-associated biochemical abnormality.
- name: Pyruvate
  presence: INCREASED
  context: Pyruvate accumulates when oxidative decarboxylation by the PDH complex is deficient.
  readouts:
  - target: Lactate and pyruvate accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated pyruvate reports impaired clearance of the glycolytic end product when oxidative decarboxylation by PDH is blocked.
    evidence:
    - reference: PMID:23467562
      reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "A deficiency of any enzyme in these pathways results in inadequate removal of pyruvate and lactate from blood and tissues and causes lactic acidosis."
      explanation: This mechanistic review supports pyruvate accumulation as a biochemical readout of impaired pyruvate oxidation.
  evidence:
  - reference: PMID:23467562
    reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A deficiency of any enzyme in these pathways results in inadequate removal of pyruvate and lactate from blood and tissues and causes lactic acidosis."
    explanation: This supports pyruvate accumulation downstream of impaired pyruvate oxidation.
- name: PDH complex enzyme activity
  presence: DECREASED
  context: Residual enzyme activity is reduced and correlates with severity in severe presentations.
  readouts:
  - target: Reduced pyruvate decarboxylation to acetyl-CoA
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Lower residual PDH complex activity directly reports the impaired pyruvate-to-acetyl-CoA catalytic step.
    evidence:
    - reference: PMID:22896851
      reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "lower residual enzyme activities than subjects who were still alive at the time of reporting."
      explanation: The clinical review supports reduced residual enzyme activity as a measurable biochemical readout of the PDH catalytic defect.
  evidence:
  - reference: PMID:22896851
    reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lower residual enzyme activities than subjects who were still alive at the time of reporting."
    explanation: This supports reduced residual PDH complex activity as a key biochemical abnormality.
genetic:
- name: PDHA1
  association: Causal X-linked pathogenic variant
  gene_term:
    preferred_term: PDHA1
    term:
      id: hgnc:8806
      label: PDHA1
  notes: PDHA1 is the most common causal gene for PDH deficiency.
  evidence:
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDHA1 | pyruvate dehydrogenase E1 subunit alpha 1 | hgnc:8806 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies PDHA1 as disease-causing for E1-alpha deficiency.
  - reference: PMID:38497591
    reference_title: Manifestations of X-linked pyruvate dehydrogenase complex deficiency in female PDHA1 carriers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pyruvate dehydrogenase complex deficiency is in up to 90% caused by pathogenic variants in the X-linked PDHA1 gene."
    explanation: This supports PDHA1 as the predominant causal gene in PDH complex deficiency.
- name: LONP1
  association: Causal germline pathogenic variant in the E1-alpha subtype record
  gene_term:
    preferred_term: LONP1
    term:
      id: hgnc:9479
      label: LONP1
  notes: >-
    Orphanet lists LONP1 alongside PDHA1 in the E1-alpha deficiency subtype
    record, and a sibling report links biallelic LONP1 variants to reduced PDH
    activity through defective LonP1 proteolysis of phosphorylated E1-alpha.
  evidence:
  - reference: ORPHA:79243
    reference_title: "Pyruvate dehydrogenase E1-alpha deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "LONP1 | lon peptidase 1, mitochondrial | hgnc:9479 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies LONP1 as disease-causing in the E1-alpha deficiency subtype record.
  - reference: PMID:30304514
    reference_title: "Bi-allelic mutations of LONP1 encoding the mitochondrial LonP1 protease cause pyruvate dehydrogenase deficiency and profound neurodegeneration with progressive cerebellar atrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified a novel homozygous missense LONP1 variant, c.2282 C > T, (p.Pro761Leu), by whole-exome and Sanger sequencing in two siblings born to healthy consanguineous parents."
    explanation: Human sibling sequencing evidence supports LONP1 as a causal germline gene for this PDH deficiency presentation.
- name: PDHB
  association: Causal biallelic pathogenic variant
  gene_term:
    preferred_term: PDHB
    term:
      id: hgnc:8808
      label: PDHB
  evidence:
  - reference: ORPHA:255138
    reference_title: "Pyruvate dehydrogenase E1-beta deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDHB | pyruvate dehydrogenase E1 subunit beta | hgnc:8808 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies PDHB as disease-causing for E1-beta deficiency.
- name: DLAT
  association: Causal biallelic loss-of-function variant
  gene_term:
    preferred_term: DLAT
    term:
      id: hgnc:2896
      label: DLAT
  evidence:
  - reference: ORPHA:79244
    reference_title: "Pyruvate dehydrogenase E2 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "DLAT | dihydrolipoamide S-acetyltransferase | hgnc:2896 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies DLAT loss-of-function variants as disease-causing for E2 deficiency.
- name: DLD
  association: Causal biallelic loss-of-function variant
  gene_term:
    preferred_term: DLD
    term:
      id: hgnc:2898
      label: DLD
  evidence:
  - reference: ORPHA:2394
    reference_title: "Pyruvate dehydrogenase E3 deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "DLD | dihydrolipoamide dehydrogenase | hgnc:2898 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies DLD loss-of-function variants as disease-causing for E3 deficiency.
- name: PDHX
  association: Causal biallelic pathogenic variant
  gene_term:
    preferred_term: PDHX
    term:
      id: hgnc:21350
      label: PDHX
  evidence:
  - reference: ORPHA:255182
    reference_title: "Pyruvate dehydrogenase E3-binding protein deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDHX | pyruvate dehydrogenase complex component X | hgnc:21350 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies PDHX as disease-causing for E3-binding protein deficiency.
- name: PDP1
  association: Causal biallelic loss-of-function variant
  gene_term:
    preferred_term: PDP1
    term:
      id: hgnc:9279
      label: PDP1
  evidence:
  - reference: ORPHA:79246
    reference_title: "Pyruvate dehydrogenase phosphatase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDP1 | pyruvate dehydrogenase phosphatase catalytic subunit 1 | hgnc:9279 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies PDP1 loss-of-function variants as disease-causing for PDH phosphatase deficiency.
treatments:
- name: Ketogenic diet
  description: >-
    Ketogenic diet is the best-supported disease-directed management strategy,
    bypassing the PDH block by providing ketone-derived acetyl-CoA and improving
    epilepsy, ataxia, sleep, language, social function, and hospitalization
    frequency in many patients.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Reduced pyruvate decarboxylation to acetyl-CoA
    treatment_effect: BYPASSES
    description: Ketogenic diet provides an alternative acetyl-CoA source downstream of the PDH block.
  evidence:
  - reference: PMID:28101805
    reference_title: "Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The treatment had a positive effect mainly in the areas of epilepsy, ataxia, sleep disturbance, speech/language development, social functioning, and frequency of hospitalizations."
    explanation: The Swedish cohort supports clinical benefit from ketogenic diet across several PDH deficiency outcomes.
  - reference: PMID:21908116
    reference_title: Pyruvate dehydrogenase deficiency and epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The use of the ketogenic diet bypasses the metabolic block, by providing a direct source of acetyl-CoA, leading to amelioration of some symptoms."
    explanation: This review directly supports the bypass mechanism for ketogenic diet in PDH deficiency.
- name: Thiamine supplementation
  description: >-
    High-dose thiamine may benefit selected thiamine-responsive PDHA1 variants,
    particularly milder movement-disorder presentations.
  treatment_term:
    preferred_term: nutritional supplementation
    term:
      id: MAXO:0000106
      label: nutritional supplementation
    therapeutic_agent:
    - preferred_term: thiamine
      term:
        id: CHEBI:18385
        label: thiamine(1+)
  target_mechanisms:
  - target: Thiamine-responsive PDHA1 residual activity
    treatment_effect: MODULATES
    description: Thiamine targets selected PDHA1/E1-alpha presentations with residual thiamine-responsive activity.
  evidence:
  - reference: PMID:26008863
    reference_title: Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia completely remitted after high doses of thiamine, remaining free of symptoms after 3 years of follow up."
    explanation: A PDHA1 case report supports high-dose thiamine responsiveness in a selected presentation.
- name: Dichloroacetate
  description: >-
    Dichloroacetate is a targeted pharmacologic approach intended to increase
    PDH complex catalytic activity and stability. Human trial evidence supports
    lactate lowering but not broad neurologic or clinical outcome improvement.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dichloroacetate
      term:
        id: CHEBI:28240
        label: dichloroacetate
  target_mechanisms:
  - target: PDK-regulated residual PDH activity
    treatment_effect: MODULATES
    description: Dichloroacetate inhibits PDK-mediated PDH inactivation and can reduce lactate.
  - target: Lactate and pyruvate accumulation
    treatment_effect: MODULATES
    description: DCA can blunt lactate increases in congenital lactic acidosis.
  evidence:
  - reference: PMID:16651305
    reference_title: Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "DCA significantly decreased the rise in blood lactate caused by carbohydrate feeding."
    explanation: A randomized trial supports lactate reduction but not global clinical benefit.
  - reference: PMID:16651305
    reference_title: Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "However, it did not improve neurologic or other measures of clinical outcome."
    explanation: The same trial limits the claim to biochemical effect rather than proven clinical improvement.
  - reference: PMID:18411236
    reference_title: Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Although continued dichloroacetate exposure is associated with evidence of peripheral neuropathy, it cannot be determined whether this is attributable mainly to the drug or to progression of underlying disease."
    explanation: Long-term follow-up supports a safety concern and reinforces that DCA is not an uncomplicated disease-modifying therapy.
  - reference: clinicaltrials:NCT02616484
    reference_title: "Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The objective of this research study is to conduct a pivotal phase 3 trial of treatment with the investigational drug dichloroacetate (DCA) in young children with deficiency of the pyruvate dehydrogenase complex (PDC)."
    explanation: The active-not-recruiting trial record supports disease-specific DCA investigation in children with PDH complex deficiency.
- name: Sodium phenylbutyrate
  description: >-
    Sodium phenylbutyrate is an investigational pharmacologic approach that can
    inhibit PDK-mediated E1-alpha phosphorylation, increase PDH complex activity
    in responsive cells and models, and is under clinical study for PDH complex
    deficiency.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sodium phenylbutyrate
      term:
        id: CHEBI:75316
        label: sodium phenylbutyrate
  target_mechanisms:
  - target: PDK-regulated residual PDH activity
    treatment_effect: MODULATES
    description: Phenylbutyrate can inhibit PDK-mediated phosphorylation and increase active PDH complex in selected models.
  evidence:
  - reference: PMID:23467562
    reference_title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Phenylbutyrate increases PDHC activity in fibroblasts from PDHC-deficient patients harboring various molecular defects"
    explanation: Patient fibroblast evidence supports increased PDH activity, but this is not a completed clinical efficacy trial.
  - reference: PMID:35996497
    reference_title: Comparison Between Dichloroacetate and Phenylbutyrate Treatment for Pyruvate Dehydrogenase Deficiency.
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Phenylbutyrate can only be used on patients with certain pathogenic variants (p.P221L, p.R234G, p.G249R, p.R349C, p.R349H) on the PDH protein."
    explanation: This review supports variant-specific, investigational use rather than universal treatment.
  - reference: clinicaltrials:NCT03734263
    reference_title: Pilot Clinical Trial to Investigate the Safety and Efficacy of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study phenylbutyrate is used for patients with pyruvate dehydrogenase complex deficiency."
    explanation: The completed Phase 2 trial record supports disease-specific clinical investigation of phenylbutyrate.
diagnosis:
- name: Biochemical testing in plasma, urine, and CSF
  description: >-
    Basic biochemical testing of plasma, urine, and CSF is used before or with
    enzyme and DNA testing, with attention to lactate, pyruvate, CSF lactate, and
    lactate:pyruvate ratio.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:23622387
    reference_title: Disorders of pyruvate metabolism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is made by enzymatic and DNA analysis after basic biochemical tests in plasma, urine, and CSF."
    explanation: This review directly supports the diagnostic sequence and sample types.
- name: Enzymatic PDH complex activity assay
  description: >-
    Enzymatic analysis confirms reduced residual PDH complex activity and helps
    distinguish PDH deficiency from other congenital lactic acidosis causes.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:23622387
    reference_title: Disorders of pyruvate metabolism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is made by enzymatic and DNA analysis after basic biochemical tests in plasma, urine, and CSF."
    explanation: This review identifies enzymatic analysis as a diagnostic component.
- name: Molecular genetic testing
  description: >-
    DNA analysis is used with biochemical and enzymatic testing to confirm PDH
    deficiency and establish the molecular subtype. The affected genes listed in
    this entry are supported by Orphanet subtype records; this diagnostic
    evidence supports DNA analysis generally rather than a specific assay design.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:23622387
    reference_title: Disorders of pyruvate metabolism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is made by enzymatic and DNA analysis after basic biochemical tests in plasma, urine, and CSF."
    explanation: This review supports DNA analysis as part of diagnosis.
- name: Brain MRI for Leigh-like and structural lesions
  description: >-
    Brain MRI can identify structural abnormalities such as ventriculomegaly,
    corpus-callosum dysgenesis, and Leigh-like lesions that support clinical
    suspicion and severity assessment.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:22896851
    reference_title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Structural brain abnormalities frequently included ventriculomegaly, dysgenesis of the corpus callosum and neuroimaging findings typical of Leigh syndrome."
    explanation: This supports MRI/neuroimaging as clinically informative for PDH deficiency.
clinical_trials:
- name: NCT02616484
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase 3 trial of dichloroacetate in young children with pyruvate
    dehydrogenase complex deficiency, using a caregiver observer-reported
    outcome survey as the primary efficacy measure.
  target_phenotypes:
  - preferred_term: Lactic acidosis
    term:
      id: HP:0003128
      label: Lactic acidosis
  evidence:
  - reference: clinicaltrials:NCT02616484
    reference_title: "Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel Observer reported outcome (ObsRO) survey that is completed by study participant's parent/caregiver, is the efficacy outcome measure."
    explanation: The trial record documents the efficacy outcome used in the Phase 3 DCA study.
- name: NCT03734263
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Pilot clinical trial investigating safety and efficacy of phenylbutyrate
    therapy in patients with PDH complex deficiency.
  evidence:
  - reference: clinicaltrials:NCT03734263
    reference_title: Pilot Clinical Trial to Investigate the Safety and Efficacy of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The aim of the study is to investigate the safety and efficacy of therapy."
    explanation: The trial record identifies phenylbutyrate safety and efficacy as the study aim.
- name: NCT03056794
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    Natural-history and advanced genetic study of children and adults with
    pyruvate dehydrogenase complex deficiencies.
  evidence:
  - reference: clinicaltrials:NCT03056794
    reference_title: "Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Children and adults with pyruvate dehydrogenase complex deficiency (PDCD) are participating in a research study seeking to better understand the genetic causes, symptoms, usefulness of current treatments, and outcomes for these disorders."
    explanation: This trial record supports ongoing natural-history and genotype-outcome data collection.
references:
- reference: ORPHA:765
  title: Pyruvate dehydrogenase deficiency
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: ORPHA:79243
  title: Pyruvate dehydrogenase E1-alpha deficiency
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: ORPHA:255138
  title: Pyruvate dehydrogenase E1-beta deficiency
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: ORPHA:79244
  title: Pyruvate dehydrogenase E2 deficiency
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: ORPHA:2394
  title: Pyruvate dehydrogenase E3 deficiency
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: ORPHA:255182
  title: Pyruvate dehydrogenase E3-binding protein deficiency
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: ORPHA:79246
  title: Pyruvate dehydrogenase phosphatase deficiency
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:22896851
  title: "The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients."
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:23622387
  title: Disorders of pyruvate metabolism.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:21908116
  title: Pyruvate dehydrogenase deficiency and epilepsy.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:28101805
  title: "Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes."
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:26008863
  title: Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:29445841
  title: Folding and assembly defects of pyruvate dehydrogenase deficiency-related variants in the E1α subunit of the pyruvate dehydrogenase complex.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:16651305
  title: Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:18411236
  title: Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:23467562
  title: Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:35996497
  title: Comparison Between Dichloroacetate and Phenylbutyrate Treatment for Pyruvate Dehydrogenase Deficiency.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: PMID:38497591
  title: Manifestations of X-linked pyruvate dehydrogenase complex deficiency in female PDHA1 carriers.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: clinicaltrials:NCT02616484
  title: "Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:"
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: clinicaltrials:NCT03734263
  title: Pilot Clinical Trial to Investigate the Safety and Efficacy of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
- reference: clinicaltrials:NCT03056794
  title: "Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)"
  found_in:
  - Pyruvate_Dehydrogenase_Deficiency-deep-research-fallback.md
review_notes: >-
  Falcon, OpenAI, OpenScientist, and Perplexity provider attempts were bounded
  and failed or timed out on 2026-05-05. The fallback research artifact records
  those failures and the PubMed, Orphanet, and ClinicalTrials.gov evidence scope
  integrated into this YAML.
📚

References & Deep Research

References

21
ORPHA:765
Pyruvate dehydrogenase deficiency
No top-level findings curated for this source.
ORPHA:79243
Pyruvate dehydrogenase E1-alpha deficiency
No top-level findings curated for this source.
ORPHA:255138
Pyruvate dehydrogenase E1-beta deficiency
No top-level findings curated for this source.
ORPHA:79244
Pyruvate dehydrogenase E2 deficiency
No top-level findings curated for this source.
ORPHA:2394
Pyruvate dehydrogenase E3 deficiency
No top-level findings curated for this source.
ORPHA:255182
Pyruvate dehydrogenase E3-binding protein deficiency
No top-level findings curated for this source.
ORPHA:79246
Pyruvate dehydrogenase phosphatase deficiency
No top-level findings curated for this source.
PMID:22896851
The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.
No top-level findings curated for this source.
PMID:23622387
Disorders of pyruvate metabolism.
No top-level findings curated for this source.
PMID:21908116
Pyruvate dehydrogenase deficiency and epilepsy.
No top-level findings curated for this source.
PMID:28101805
Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes.
No top-level findings curated for this source.
PMID:26008863
Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review.
No top-level findings curated for this source.
PMID:29445841
Folding and assembly defects of pyruvate dehydrogenase deficiency-related variants in the E1α subunit of the pyruvate dehydrogenase complex.
No top-level findings curated for this source.
PMID:16651305
Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children.
No top-level findings curated for this source.
PMID:18411236
Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate.
No top-level findings curated for this source.
PMID:23467562
Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
No top-level findings curated for this source.
PMID:35996497
Comparison Between Dichloroacetate and Phenylbutyrate Treatment for Pyruvate Dehydrogenase Deficiency.
No top-level findings curated for this source.
PMID:38497591
Manifestations of X-linked pyruvate dehydrogenase complex deficiency in female PDHA1 carriers.
No top-level findings curated for this source.
clinicaltrials:NCT02616484
Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:
No top-level findings curated for this source.
clinicaltrials:NCT03734263
Pilot Clinical Trial to Investigate the Safety and Efficacy of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.
No top-level findings curated for this source.
clinicaltrials:NCT03056794
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)
No top-level findings curated for this source.

Deep Research

1
Pyruvate Dehydrogenase Deficiency Deep Research Fallback ▸

Pyruvate Dehydrogenase Deficiency Deep Research Fallback

Provider Attempts

  • 2026-05-05T19:39Z: just research-disorder falcon "Pyruvate dehydrogenase deficiency" failed before provider execution because the disorder YAML file had not yet been created.
  • 2026-05-05T19:42Z: direct deep-research-client research with provider falcon produced no output during the bounded 240 second wait and was terminated by timeout.
  • 2026-05-05T19:47Z: direct deep-research-client research with provider openai produced no output during the bounded 180 second wait and was terminated by timeout.
  • 2026-05-05T19:52Z: direct deep-research-client research with provider openscientist produced no output during the bounded 180 second wait and was terminated by timeout.
  • 2026-05-05T20:07Z: direct deep-research-client research with provider perplexity failed immediately with a 401 quota error.

No provider-generated deep-research narrative was available within the bounded runtime. Curation therefore proceeded from regenerated structured Orphanet records, fetched PubMed caches, fetched ClinicalTrials.gov caches, and direct NCBI/ClinicalTrials.gov metadata checks. No references_cache/*.md file was created or edited by hand.

Evidence Scope Used For Curation

  • ORPHA:765 for the disease definition, inheritance, age of onset, prevalence, exact MONDO mapping, broad OMIM subtype mappings, and structured root HPO phenotype rows.
  • ORPHA:79243, ORPHA:255138, ORPHA:79244, ORPHA:2394, ORPHA:255182, and ORPHA:79246 for the six recognized PDH complex subunit/regulatory subtypes, exact subtype MONDO/OMIM cross-references, and disease-causing gene rows.
  • PMID:22896851 for the 371-patient clinical, biochemical, neuroimaging, and natural-history spectrum.
  • PMID:23622387 for diagnostic approach, PDH complex architecture, major subtypes, and sex-linked PDHA1 presentation patterns.
  • PMID:21908116 for the PDH complex glycolysis-to-TCA role, epilepsy mechanism, structural brain-anomaly mechanism, and ketogenic-diet bypass rationale.
  • PMID:28101805 for human clinical ketogenic-diet outcomes in 19 Swedish pediatric patients.
  • PMID:26008863 for thiamine-responsive PDHA1-associated paroxysmal exercise-induced dystonia.
  • PMID:29445841 for E1-alpha folding/assembly defects and impaired PDC activity.
  • PMID:16651305 and PMID:18411236 for dichloroacetate clinical-trial evidence, lactate reduction, lack of broad clinical-outcome improvement, and neuropathy safety signal.
  • PMID:23467562 and PMID:35996497 for phenylbutyrate mechanism, in vitro/model evidence, variant-specific potential responsiveness, and the comparative DCA/phenylbutyrate treatment landscape.
  • clinicaltrials:NCT02616484 for the active-not-recruiting Phase 3 dichloroacetate trial, clinicaltrials:NCT03734263 for the completed Phase 2 phenylbutyrate trial, and clinicaltrials:NCT03056794 for the recruiting natural-history/genetic study.

Curation Conclusions

Pyruvate dehydrogenase deficiency is best represented as a genetically heterogeneous neurometabolic mitochondrial disorder in which defects in PDH complex structural subunits or regulatory phosphatase reduce conversion of pyruvate to acetyl-CoA. The metabolic block links glycolysis to inadequate TCA cycle substrate supply, pyruvate/lactate accumulation, lactic acidosis, and energy failure in the developing brain. Human cohort and review evidence supports neurodevelopmental delay, hypotonia, seizures, corpus-callosum and ventricular abnormalities, Leigh-like neuroimaging, and early mortality in the severe neonatal end of the spectrum. Treatment evidence is strongest for ketogenic diet as a bypass strategy providing acetyl-CoA through fatty-acid oxidation/ketosis; thiamine responsiveness exists in selected PDHA1 variants; dichloroacetate and sodium phenylbutyrate remain targeted pharmacologic or investigational approaches with biochemical rationale and limited or mixed clinical evidence.